



CLINICAL GUIDELINES

OB Ultrasound Imaging Policy

Version 1.0.2019

Effective February 15, 2019



eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual's Primary Care Physician (PCP) may provide additional insight.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Obstetrical Ultrasound Imaging Guidelines

Abbreviations and Glossary for OB Ultrasound Imaging Guidelines	5
OB-GEN: Obstetrical Ultrasound Imaging General Guidelines	6
OB-GEN.1: Required Documentation	6
OB-GEN.2: Inappropriate Use of OB Ultrasound	6
OB-1: Vaginal Bleeding and/or Abdominal/Pelvic Pain/Cramping with or without Trauma	7
OB-1.1: Abdominal Pain	8
OB-1.2: Trauma	8
OB-1.3: Vaginal Bleeding and/or Abdominal/Pelvic Pain	9
OB-1.4: Ectopic Pregnancy	9
OB-1.5: Spontaneous Abortion	10
OB-1.6: Hydatidiform Mole	10
OB-2: Abnormal Fetal Position or Presentation	11
OB-2.1: Abnormal Fetal Position or Presentation	12
OB-3: Alloimmunization/ Rh Isoimmunization/ Other Causes of Fetal Anemia/ Parvo/ Hydrops	13
OB-3.1: Alloimmunization/ RH Isoimmunization/ Other Causes of Fetal Anemia	14
OB-3.2: Exposure to Parvovirus B-19	15
OB-3.3: Twin Anemia Polycythemia Sequence	15
OB-3.4: Fetal Hydrops Associated with Polyhydramnios	15
OB-3.5: Sustained Fetal Tachycardia	15
OB-4: Amniotic Fluid Abnormalities/ Oligohydramnios/ Polyhydramnios	17
OB-4.1: Amniotic Fluid Abnormalities	18
OB-5: Fetal Anatomic Scan	20
OB-5.1: Initial Screening for Fetal Anomalies	21
OB-5.2: Follow-Up	21
OB-6: No Fetal Heart Tone/Decreased Fetal Movement	23
OB-6.1: No Fetal Heart Tone/Decreased Fetal Movement	24
OB-7: Fetal Echocardiography (ECHO)	25
OB-7.1: Indications for Fetal Conditions	26
OB-7.2: Indications for Maternal Conditions	27
OB-8: Fetal Growth Problems	29
OB-8.1: Fetal Growth Restriction Current Pregnancy	30
OB-8.2: Macrosomia-Large for Dates Current Pregnancy	31
OB-9: Placental or Cord Abnormalities	33
OB-9.1: Vasa Previa	34
OB-9.2: Placental or Cord Abnormalities	34
OB-9.3: Subchorionic Hematoma or Placental Hematoma	34
OB-9.4: Suspected Abruption Placentae	35
OB-9.5: Placenta Previa	35
OB-9.6: Placenta Accreta/Placenta Percreta	36

OB-10: Fetal Aneuploidy and Anomaly Screening	38
OB-10.1: First Trimester Screening	39
OB-10.2: Second Trimester Screening	40
OB-11: High Risk Pregnancy	43
OB-11.01: High Risk Pregnancy Special Considerations	44
OB-11.1: High Risk Group One-Risk Factors	44
OB-11.2: High Risk Group Two – Findings on Ultrasound That May Require Further Imaging	46
OB-11.3: High Risk Group Three – BMI	47
OB-11.4: High Risk Group Four	48
OB-11.5: High Risk Group Five: Zika Virus	49
OB-11.6: High Risk Group 6 – Pre-Gestational Diabetes on Oral Medications or Insulin	49
OB-11.7: High Risk Group Seven Gestational Diabetes	51
OB-11.8: Hypertension	53
OB-11.9: Single Umbilical Artery	54
OB-11.10: History of Pre-Term Delivery/History of PPRM	54
OB-11.11: History of Stillbirth	55
OB-12: History of Infertility	59
OB-12.1: History of Infertility	60
OB-12.2: Present Pregnancy with use of Fertility Drugs and Treatment (ART)	60
OB-13: Cervical Insufficiency/Current Preterm Labor	61
OB-13.1: Cervical Insufficiency	62
OB-13.2: Cerclage in place in current pregnancy	62
OB-13.3: Current Preterm Labor	62
OB-14: Intrauterine Device (IUD)	64
OB-14.1: Locate an Intrauterine Device	65
OB-15: Macrosomia	66
OB-16: Multiple Pregnancies	67
OB-16.1: For Suspected multiple pregnancies:	68
OB-16.2: For Known dichorionic multiple pregnancies:	68
OB-16.3: For Known monochorionic-diamniotic or monochorionic-monoamniotic multiple pregnancies	69
OB-17: Previous C-section or History of Uterine Scar	72
OB-17.1: Previous C-section or history of uterine scar	73
OB-18: Post Date Pregnancy	74
OB-18.1: Late-Term/Postterm Pregnancy	75
OB-19: Preterm/Prelabor Rupture of Membranes	76
OB-19.1: Current Preterm Prelabor Rupture of Membranes (PPROM)	77
OB-19.2: Current Prelabor Rupture of Membranes (PROM)	77
OB-20: Third Trimester Imaging	78
OB-20.1: Third Trimester Imaging – Ultrasound	79
OB-21: Uncertain Dates	80
OB-21.1: Uncertain Dates/Unknown Last Menstrual Period(LMP)	81

OB-22: Unequal Fundal Size and Dates	82
OB-22.1: Unequal Fundal Size and Dates	83
OB-23: Adnexal mass/Uterine Fibroids and Uterine Anomalies	84
OB-23.1: Adnexal Mass	85
OB 23.2: Uterine fibroids in pregnancy	85
OB 23.3: Uterine anomalies in pregnancy	86
OB-24: Procedure Coding Basics for Established Pregnancy	88
Procedure Coding Basics for Established Pregnancy General Considerations	89
OB-24.1: OB Ultrasound Code Selection	90
OB-24.2: Required Elements for First Trimester OB Ultrasound	91
OB-24.3: Required Elements for Second or Third Trimester Fetal Anatomic Evaluation OB Ultrasound	92
OB-24.4: Required Elements for a Detailed Fetal Anatomic Evaluation OB Ultrasound	94
OB-24.5: Fetal Nuchal Translucency	97
OB-24.6: Limited and Follow-Up Studies	98
OB-24.7: Obstetric Transvaginal Ultrasound	99
OB-24.8: Biophysical Profile (BPP)	99
OB-24.9: Fetal Doppler	100
OB-24.10: Duplex Scan (Uterine Artery)	102
OB-24.11: Fetal Echocardiography	104
OB-24.12: 3D and 4D Rendering	105
OB-24.13: Fetal MRI	106
OB-25: High Risk Medications and Substances	108
OB-26: Imaging for Planned Pregnancy Termination	110

Abbreviations and Glossary for OB Ultrasound Imaging Guidelines

ACOG	American College of Obstetricians and Gynecologists
AFI	amniotic fluid index
AFP	alpha-fetoprotein
CST	contraction stress test
B-mode (brightness)	a two dimensional imaging procedure, B-mode ultrasound is the basis for all static and real time B-scan images
BPP	Biophysical Profile includes the ultrasound variables: fetal breathing, muscle tone, and movement as well as amniotic fluid volume. BPP may be performed with or without a non-stress test (NST) which involves fetal heart rate (FHR) monitoring.
D & C/D & E	dilatation and curettage/ Dilation and Evacuation
dichorionic twins	twins having distinct chorions (membrane that forms the fetal part of the placenta), including monozygotic twins (from one oocyte [egg]) separated within 72 hours of fertilization and all dizygotic twins (from two oocytes fertilized at the same time
Doppler	involves measuring a change in frequency when the motion of vascular flow is measured
EDC	Estimated Date of Confinement; determined from the first day of the last menstrual cycle
FHR	fetal heart rate
hCG	human chorionic gonadotropin
IDDM	insulin-dependent diabetes mellitus
FGR	Fetal growth restriction; an estimated or actual weight of the fetus below 10 th percentile for gestational age
M-mode	an ultrasound imaging technique in which structure movement can be depicted in a wave-like manner; primarily used in cardiac and fetal cardiac imaging
macrosomia	estimated fetal weight of greater than 4000 or 4500 grams
monochorionic twins	twins developed from one oocyte (egg) developing with a single chorions (membrane that forms the fetal part of the placenta)
NICU	Neonatal Intensive Care Unit
NST	fetal non-stress test
oligohydramnios	diminished amniotic fluid volume (AFV) for gestational age; definitions include: 1.) maximum deepest pocket of ≤ 2 cm, and, 2.) AFI of ≤ 5 cm or $<$ the 5 th percentile for gestational age
PACS	Picture Archiving and Communications System
polyhydramnios	1.) AFI ≥ 24 cm, or maximum vertical pocket of ≥ 8 cm
PROM	preterm rupture of membranes
quad screen	alpha-fetoprotein (AFP), estriol, human chorionic gonadotropin (hCG), inhibin A
real time scan	considered the most common type of ultrasound; a 2-dimensional scan that reflects structure and motion over time, scanning and display of images are run at a sufficiently rapid rate so that moving structures can be viewed moving at their natural rate; frame rates ≥ 15 frames per second are considered "real time"

OB-GEN: Obstetrical Ultrasound Imaging General Guidelines

OB-GEN.1: Required Documentation

- An evaluation of pregnancy with history and physical exam (an initial office visit) is necessary prior to obstetric ultrasound imaging requests
- The following information must be submitted with each request:
 - ◆ Anticipated date of service
 - ◆ Expected date of delivery
 - ◆ Gestational age at date of service
 - ◆ Results of prior ultrasound studies if available

OB-GEN.2: Inappropriate Use of OB Ultrasound

- Obstetrical ultrasound studies cannot be authorized for payment for individuals who do not have a positive pregnancy test or clinical evidence of a pregnancy (fetal heart tones)
- Obstetrical ultrasound is **not** appropriate for the following:
 - ◆ Sex determination only
 - ◆ To provide a keepsake or souvenir picture

Practice Note

In the absence of other specific indications, the optimal time for a single ultrasound examination is at 18 to 22 weeks of gestation. This timing allows for a survey of fetal anatomy in most women and an accurate estimation of gestational age.²

References

1. Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society of Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. *Obstet Gynecol Survey*. 2014;69(8):453-455. Accessed November 3, 2017.
http://journals.lww.com/obgynsurvey/Abstract/2014/08000/Fetal_Imaging_Executive_Summary_of_a_Joint.4.aspx.
2. Practice Bulletin No. 175 Summary. *Obstetrics & Gynecology*. 2016;128(6):1459-1460. doi:10.1097/aog.0000000000001812.
http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.

OB-1: Vaginal Bleeding and/or Abdominal/Pelvic Pain/Cramping with or without Trauma

OB-1.1: Abdominal Pain	8
OB-1.2: Trauma	8
OB-1.3: Vaginal Bleeding and/or Abdominal/Pelvic /Pain	9
OB-1.4: Ectopic Pregnancy	9
OB-1.5: Spontaneous Abortion	10
OB-1.6: Hydatidiform Mole	10

OB-1.1: Abdominal Pain

For abdominal pain or trauma that presents without bleeding:

- Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated **or**
 - ◆ CPT® 76801 and/or CPT® 76817 when complete ultrasound has not yet been performed, if less than 14 weeks **or**
 - ◆ CPT® 76805 (plus CPT® 76810 if more than one fetus) if equal to or greater than 14 weeks, when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed.

OB-1.2: Trauma

Trauma

- Blunt trauma in the first trimester (prior to 13 weeks) generally does not cause pregnancy loss with the exception of profound hypotension:
 - ◆ No imaging is indicated unless there is cramping and/or bleeding.
- Blunt trauma between 13-20 weeks gestation:
 - ◆ CPT® 76801 and/or CPT® 76817 when complete ultrasound has not yet been performed, if less than 14 weeks
 - ◆ Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated **or**
 - ◆ CPT® 76805 (plus CPT® 76810 if more than one fetus) if equal to or greater than 14 weeks, when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed.

Management of outpatient trauma implies that the trauma was not serious enough to be treated as inpatient. The major risk is abruptio placentae:

- Monitor for uterine contractions for those > 20 weeks
- CPT® 76805 (plus CPT® 76810 if more than one fetus) when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed, **or**
- CPT® 76815 or
- CPT® 76816 (if a complete anatomy ultrasound was done previously)
 - ◆ Additionally, if greater than 24 weeks, BPP CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI can be considered
- Other advanced imaging may be indicated, send for Medical Director review

Reference

1. Brown HL. Trauma in Pregnancy. Obstetrics & Gynecology. 2009;114(1):147-160.
https://journals.lww.com/greenjournal/Abstract/2009/07000/Trauma_in_Pregnancy.25.aspx.
 Accessed August 10, 2018.

OB-1.3: Vaginal Bleeding and/or Abdominal/Pelvic Pain

First Trimester

- Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated **or**
- CPT® 76801 when complete ultrasound has not yet been performed, if less than 14 weeks and/or CPT® 76817 may be performed once when medically indicated for complete ultrasound.

Second and Third Trimesters

- CPT® 76815 and/or CPT® 76817 or
- CPT® 76816 if a complete ultrasound was done previously and/or CPT® 76817
- Additionally, if greater than 24 weeks, BPP CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI can be considered

Reference

1. Practice Bulletin No. 150. Obstetrics & Gynecology. 2015;125(5):1258-1267. doi:10.1097/01.aog.0000465191.27155.25. Reaffirmed 2017.

OB-1.4: Ectopic Pregnancy

Ectopic Pregnancy

First Trimester

- Signs and symptoms of ectopic pregnancy include pain and/or bleeding
 - ◆ Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated **or**
 - ◆ CPT® 76801 when complete ultrasound has not yet been performed, if less than 14 weeks and/or CPT® 76817 may be performed once when medically indicated for complete ultrasound
 - ◆ If patient has a history of ectopic pregnancy with non-doubling hCG without pain and bleeding, ultrasound can be performed (CPT® 76801 and/or CPT® 76817) to confirm an intrauterine pregnancy
 - ◆ If ectopic pregnancy is being treated non-surgically with Methotrexate, imaging may be required per **OB-1: Vaginal Bleeding and/or Abdominal/Pelvic Pain/Cramping with or without Trauma** or the imaging guidelines above for ectopic pregnancy

Reference

1. ACOG Practice Bulletin No. 193. Obstetrics & Gynecology. 2018;131(3). doi:10.1097/aog.0000000000002560.

OB-1.5: Spontaneous Abortion

Spontaneous Abortion	
➤	For <u>spontaneous abortion</u> (miscarriage), ultrasound can be performed to evaluate threatened or missed abortion (with or without vaginal bleeding prior to 20 weeks)
◆	Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated or
◆	CPT® 76801 when complete ultrasound has not yet been performed, if less than 14 weeks and/or CPT® 76817 may be performed once when medically indicated for complete ultrasound
◆	Repeat ultrasound (CPT® 76815 or CPT® 76816 if a complete anatomic ultrasound was done previously and/or CPT® 76817) is appropriate in the setting of rising or non-falling serum hCG levels at weekly intervals
◆	Ultrasound imaging can be repeated earlier than seven days if there are new symptoms
➤	For <u>complete spontaneous abortion</u> , ultrasound is generally not indicated if there is no pain, no ongoing bleeding, and hCG levels are decreasing

Reference

1. Practice Bulletin No. 200. Obstetrics & Gynecology. August 2018:1.
doi:10.1097/aog.0000000000002899

OB-1.6: Hydatidiform Mole

- See also: **PV-16.1: Molar Pregnancy and GTN**

Hydatidiform Mole	
First, Second and Third Trimester	
➤	Ultrasound can be performed for diagnosis of hydatidiform mole
◆	Initially CPT® 76815 and/or CPT® 76817 for limited ultrasound when medically indicated or
◆	CPT® 76801, when complete ultrasound has not yet been performed, if less than 14 weeks, and/or CPT® 76817 may be performed once when medically indicated for complete ultrasound
➤	Following treatment with D & C and/or Methotrexate, serial serum hCG values are measured until they become negative
◆	Ultrasound may be necessary for follow-up (CPT® 76830 and CPT® 76856 or CPT® 76856 if hCG titers are not decreasing as expected, are increasing following treatment, or if there is onset of pain despite falling hCG titers.

References

1. ACOG Practice Bulletin #53: Diagnosis and Treatment of Gestational Trophoblastic Disease. Obstetrics & Gynecology. 2004 (Reaffirmed 2016);103(6):1365-1377.
https://journals.lww.com/greenjournal/Citation/2004/06000/ACOG_Practice_Bulletin_53_Diagnosis_and.51.aspx. Accessed August 10, 2018

OB-2: Abnormal Fetal Position or Presentation

OB-2.1: Abnormal Fetal Position or Presentation

12

OB-2.1: Abnormal Fetal Position or Presentation

- Confirmation of suspected abnormal fetal position or presentation (transverse or breech presentation):
 - ◆ An ultrasound can be performed at 36 weeks gestation or greater to determine fetal position to allow for external cephalic version
 - ◆ Ultrasound to determine fetal position is not necessary prior to 36 weeks gestation unless delivery is imminent

Coding Notes

- Report one of the following:
 - ◆ CPT® 76805 (plus CPT® 76810 if more than one fetus) for complete fetal anatomic scan when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed **or**
 - ◆ CPT® 76815 for limited ultrasound

Practice Note

Fetal presentation should be assessed by abdominal palpation at 36 weeks or later, when presentation is likely to influence the plans for the birth. Routine assessment of presentation by abdominal palpation should not be offered before 36 weeks because it is not always accurate and may be uncomfortable. Suspected fetal malpresentation should be confirmed by an ultrasound assessment.

Reference

1. Practice Bulletin No. 161 Summary. Obstetrics & Gynecology. 2016;127(2):412-413.
doi:10.1097/aog.0000000000001305

OB-3: Alloimmunization/ Rh Isoimmunization/ Other Causes of Fetal Anemia/ Parvo/ Hydrops

OB-3.1: Alloimmunization/RH Isoimmunization/Other Causes of Fetal Anemia	14
OB-3.2: Exposure to Parvovirus B-19	15
OB-3.3: Twin Anemia Polycythemia Sequence	15
OB-3.4: Fetal Hydrops Associated with Polyhydramnios	15
OB-3.5: Sustained Fetal Tachycardia	15

OB-3.1: Alloimmunization/ RH Isoimmunization/ Other Causes of Fetal Anemia

Fetal anemia and hydrops may be a result of immune conditions, such as red-cell or Kell alloimmunization, non-immune hydrops caused by parvovirus B19 infection or any other known acquired or congenital causes of fetal anemia.

Imaging for Alloimmunization/ RH Isoimmunization:	
➤	Ultrasound (CPT® 76816) every 2 to 4 weeks to assess fetal growth starting after performance of the fetal anatomic scan CPT® 76811 at 16 weeks or greater. If less than 16 weeks, send to MD Review
➤	Weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST starting at 32 weeks or sooner depending on fetal condition
➤	3a. Weekly fetal middle cerebral artery MCA Doppler (CPT® 76821) starting at 20 weeks or sooner depending on fetal condition when any one of the following maternal antibody titers are $\geq 1:8$ ◆ Rhesus antibodies (Cc/Dd/Ee) ◆ Anti-Duffy (anti-fya) antibody and/or ◆ Anti-Kidd antibody
➤	3b. With Anti-Kell antibody (any antibody titer) MCA Doppler (CPT® 76821) once weekly
➤	3c. Evidence of fetal hydrops on previous imaging once weekly MCA Doppler (CPT® 76821)
➤	3d. Prior pregnancy associated with HDFN (hemolytic disease of the fetus and newborn) once weekly MCA Doppler (CPT® 76821)
➤	Because MCA-PSV increases across gestation, results should be adjusted for gestational age. Measurements can be initiated as early as 16 weeks of gestation if there is a past history of early severe fetal anemia or very high titers. The optimal interval between examinations has not been determined, but should be one to two weeks based on clinical experience and what is known about progression of fetal anemia in this setting

Practice Note-

Other antigens not listed above, may be associated with hemolytic disease of the fetus and newborn and may require fetal assessment as in OB-3.1 if maternal antibody titers are $\geq 1:8$. Please send these cases to medical review. Some of these antigens include MNSsM, MNSsS, MNSss, MNSsU, MNSsMi, MSSsMT, Diego D1, Diego Di, PPPTj, Public antigen Yt, Public antigen En, Public antigen Co2. Private antigens-Biles, Good, Heibel, Radin, Wright, and ZD. Dia, Dib ,PP1Pk, Far, Good, Lan, LW, Mta, U ,Wr a.

OB-3.2: Exposure to Parvovirus B-19

- Parvovirus B-19 (Fifth Disease):
 - ◆ Ultrasound (CPT® 76816) every 2 to 4 weeks to assess fetal growth starting at time of known exposure and continuing for 8 to 10 weeks post-exposure
 - ◆ Weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST starting at time of known exposure if ≥ 24 weeks gestation and continuing for 8 to 12 weeks post-exposure
 - ◆ Fetal middle cerebral artery (MCA) Doppler (CPT® 76821) every 1 to 2 weeks, starting at time of known exposure, if 16 weeks or greater and continuing for 8 to 12 weeks post-exposure

OB-3.3: Twin Anemia Polycythemia Sequence

- See: **OB-16.3: For Known monochorionic-diamniotic or monochorionic-monoamniotic multiple pregnancies**

OB-3.4: Fetal Hydrops Associated with Polyhydramnios

- Fetal hydrops associated with Polyhydramnios: if diagnosed with hydrops, image according to **OB-3.1: Alloimmunization/RH Isoimmunization/Other Causes of Fetal Anemia**

OB-3.5: Sustained Fetal Tachycardia

- Sustained fetal tachycardia with a structurally normal fetal echocardiogram and fetal anemia is suspected as the cause of the tachycardia, may have CPT® 76821 one time

Practice Notes

Rhesus isoimmunization/alloimmunization is the process through which fetal Rh+ red blood cells enter the circulation of an Rh negative mother causing her to produce antibodies which can cross the placenta and destroy the red blood cells of the current Rh+ fetus in subsequent Rh+ pregnancies.

Twin anemia polycythemia sequence (TAPS) may occur spontaneously in up to 5% of monochorionic twins and may also develop after incomplete laser treatment in twin-twin transfusion syndrome (TTTS) cases. As with TTTS the underlying mechanism is thought to be abnormal placental vascular anastomoses. One twin develops anemia and the other polycythemia. One of the features suggesting towards the diagnosis is discordance in fetal middle cerebral artery peak systolic velocity (MCA-PSV) measurements

Peak systolic velocity (PSV) of the fetal middle cerebral artery can be used as a substitute for amniocentesis to evaluate a fetus at risk for anemia due to Rhesus isoimmunization/alloimmunization

References

1. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. *N Engl J Med*. 2000;342(1):9-14. August 10, 2018. <http://www.nejm.org/doi/full/10.1056/NEJM200001063420102>.
2. ACOG Practice Bulletin No. 192 Summary. *Obstetrics & Gynecology*. 2018;131(3):611-612. https://journals.lww.com/greenjournal/Abstract/2018/03000/ACOG_Practice_Bulletin_No_192_Summary.41.aspx. Accessed August 10, 2018
3. Lamont RF, Sobel JD, Vaisbuch E, et al. Parvovirus B19 infection in human pregnancy. *Brit J Obstet Gynecol*. 2011;118:175-186. August 10, 2018. <http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2010.02749.x/abstract>.
4. Reddy UM, Filly RA, and Copel JA. Prenatal imaging: ultrasonography and magnetic resonance imaging. *Obstet Gynecol*. 2008;112(1):145-157. August 10, 2018. <http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2008&issue=07000&article=00024&type=abstract>
5. Reddy UM, Abuhamad AZ, Levine D et al. Fetal Imaging: executive summary of a joint Eunice Kennedy Shriver National Institute Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society of Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. *Obstet Gynecol Survey*. 2014;69(8):453-455. August 10, 2018. http://journals.lww.com/obgynsurvey/Abstract/2014/08000/Fetal_Imaging_Executive_Summary_of_a_Joint.4.aspx
6. Mari G, Norton ME, Stone J, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical guideline No. 8: The fetus at risk for anemia: diagnosis and management. *Am J Obstet Gynecol*. 2015;212(6):697-710. Accessed August 10, 2018. [http://www.ajog.org/article/S0002-9378\(15\)00203-3/pdf](http://www.ajog.org/article/S0002-9378(15)00203-3/pdf).
7. Crane J, Mundle W, and Boucoiran I. SOGC Clinical Practice Guideline No. 316. Parvovirus B19 Infection in Pregnancy. *J Obstet and Gynecol Canada*. 2014;36(12):1107-1116. Accessed August 10, 2018. [http://www.jogc.com/article/S1701-2163\(15\)30390-X/fulltext](http://www.jogc.com/article/S1701-2163(15)30390-X/fulltext).
8. Practice Bulletin No. 151. Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. *Obstet Gynecol*. 2015 Jun;125(6):1510-1525. Reaffirmed 2017. Accessed August 10, 2018. https://journals.lww.com/greenjournal/Citation/2015/06000/Practice_Bulletin_No_151_Cytomegalovirus.54.aspx

OB-4: Amniotic Fluid Abnormalities/ Oligohydramnios/ Polyhydramnios

OB-4.1: Amniotic Fluid Abnormalities

18

OB-4.1: Amniotic Fluid Abnormalities

For suspected polyhydramnios or oligohydramnios:	
➤	One ultrasound is appropriate
➤	CPT® 76805 (plus CPT® 76810 if more than one fetus) for complete fetal anatomic scan when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed or
➤	If complete fetal anatomic scan CPT® 76805 was previously performed:
◆	CPT® 76815 for limited ultrasound or
◆	CPT® 76816 for complete ultrasound (if complete anatomy ultrasound was done previously)
For confirmed diagnosis of polyhydramnios: AFI ≥ 24cm or maximum deepest vertical pocket ≥ 8cm.	
➤	Detailed Fetal Anatomic Scan (CPT® 76811) upon diagnosis if not already performed
➤	One ultrasound (CPT® 76816)
◆	Starting at ≥ 23 weeks, every 3 to 4 weeks for mild polyhydramnios; AFI ≥ 24 cm to 30 cm or maximum deepest vertical pocket ≥ 8 cm to 10 cm
◆	Starting at ≥ 23 weeks, every 2 weeks for severe polyhydramnios; AFI > 30 or maximum deepest vertical pocket is > 10 cm
➤	Starting at 26 weeks, weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST, if maximum vertical pocket is ≥ 8 cm or if AFI ≥ 24 cm.
➤	Starting at 26 weeks, twice-weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST, if maximum deepest vertical pocket is ≥ 10 cm or an AFI ≥ 30
➤	One time fetal echo if initial echo has not already been performed (CPT® 76825 and/or CPT® 76827 and/or CPT® 93325. All requests for follow-up echo go to Medical Director review.
For confirmed diagnosis of oligohydramnios: AFI ≤ 5 cm or maximum vertical pocket ≤ 2 cm	
➤	May have CPT® 76811 if not already performed
➤	<u>Starting at ≥ 23 weeks</u> , one ultrasound (CPT® 76816) every 2 to 4 weeks for fetal growth
➤	Starting at 26 weeks, weekly biophysical profile (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST, if maximum vertical pocket ≤ 2 cm or AFI ≤ 5 cm. If less than 26 weeks send to Medical director review
➤	Starting at time of diagnosis, weekly umbilical artery Doppler (CPT® 76820)

Practice Notes

Polyhydramnios refers to excessive amniotic fluid volume. It is determined with AFI ≥ 24 cm or (greater than the 95th percentile by gestational age), or maximum deepest vertical pocket ≥ 8 cm.

Oligohydramnios refers to diminished amniotic fluid volume. At 30 weeks or greater, it is determined with AFI ≤ 5 cm by measuring fluid in each of the four quadrants or by the maximum single deepest vertical pocket ≤ 2 cm (is the best definition of oligohydramnios). At less than 30 weeks, oligohydramnios is determined by a gestation age cut off of ≤ 5 percentile

Polyhydramnios can be an early presenting finding of fetal hydrops associated with fetal anemia. Middle cerebral artery Doppler is commonly used to diagnose whether this fetal anemia is present or not. See: **OB-3.1: Alloimmunization/RH Isoimmunization/Other Causes of Fetal Anemia.**

Polyhydramnios may also present as a finding of cardiac dysfunction, fetal arrhythmias or cardiac malformation. Fetal echocardiography is commonly performed to determine if any other conditions are present or not. **See: OB-7: Fetal Echocardiography (ECHO)**

References

1. Practice Bulletin No. 175 Summary. Obstetrics & Gynecology. 2016;128(6):1459-1460. doi:10.1097/aog.0000000000001812.
2. Practice Bulletin No. 145. Obstetrics & Gynecology. 2014;124(1):182-192. doi:10.1097/01.aog.0000451759.90082.7b
3. Wax J, Minkoff H, Johnson A, et al. Consensus Report on the Detailed Fetal Anatomic Ultrasound Examination. Journal of Ultrasound in Medicine. 2014;33(2):189-195. doi:10.7863/ultra.33.2.189 .

OB-5: Fetal Anatomic Scan

OB-5.1: Initial Screening for Fetal Anomalies	21
OB-5.2: Follow-Up	21

OB-5.1: Initial Screening for Fetal Anomalies

- A fetal anatomic scan to screen for anomalies is ideally performed at 18 to 20 weeks, but may be performed after week ≥ 16 . If less than 16 weeks gestation, send to MD review
 - ◆ CPT® 76817 transvaginal ultrasound can be considered if the cervical length is less than or equal to 3.0 cm with transabdominal ultrasound measurement
 - ◆ Reported as CPT® 76805 if the patient is **not** high risk
 - ◆ If pregnancy is high risk report as (CPT® 76811). A detailed fetal anatomic scan (CPT® 76811) is performed by a Maternal Fetal Medicine (MFM)/Perinatologist Radiologist, or AIUM or ACR accredited facilities as the screening anatomic study. See: **OB-11: High Risk Pregnancy**

OB-5.2: Follow-Up

- Follow-up ultrasounds (CPT® 76816) can be performed every 3 to 6 weeks to evaluate fetal growth if pregnancy is high risk see **OB-11: High Risk Pregnancy**
- Follow-up ultrasound (CPT® 76815 or CPT® 76816) can be performed if indeterminate, incomplete or equivocal finding on initial fetal anatomic scan once. A limited ultrasound CPT® 76815 if limited to a follow up of a single item
- Detailed anatomy ultrasound CPT® 76811 can be performed if not previously performed when initial fetal anatomic scan CPT® 76805 is abnormal see: **OB-11: High risk Pregnancy**

Coding Notes

Fetal Anatomic Scan - Coding Notes	
CPT® 76805	➤ A complete transabdominal ultrasound (CPT® 76805). See: <u>OB-24.3: Required Elements for Second or Third Trimester Fetal Anatomic Evaluation OB Ultrasound</u>
CPT® 76810	➤ CPT® 76810 is an add-on code used with the primary procedure CPT® 76810 to report each additional fetus if there is a multiple gestation
CPT® 76805 CPT® 76810	➤ CPT® 76805 and CPT® 76810 should only be reported once per pregnancy unless the mother changes to a new medical caregiver at a new office, and there is a medical indication for ultrasound
CPT® 76811 CPT® 76812	➤ CPT® 76811 and CPT® 76812 are defined as including all of the requirements listed for procedures CPT® 76805 and CPT® 76810 plus additional detailed anatomic examination. The pregnancy must also be high risk to support CPT® 76811 and CPT® 76812. In addition the report must include the detailed elements found in OB 24.4. See: <u>OB-24.4: Required Elements for a Detailed Fetal Anatomic Evaluation OB Ultrasound</u>
CPT® 76812	➤ CPT® 76812 is an add-on code used with the primary procedure CPT® 76812 to report each additional fetus in a multiple gestation
CPT® 76811	➤ The reporting of CPT® 76811 only once per pregnancy, per practice (per NPI) is appropriate
CPT® 76815	➤ CPT® 76815 describes a limited or “quick look” study used to report one or more of the elements listed in the code definition, i.e. “fetal heartbeat”, placental location or fluid check

CPT® 76816	➤ CPT® 76816 describes a follow-up ultrasound (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), trans-abdominal approach, per fetus. ◆ The use of this CPT code is reserved for subsequent follow up ultrasound only; i.e. An ultrasound must have been performed previously. ◆ Components include: Focused assessment of fetal size by measuring BPD, abdominal circumference, femur length, or other appropriate measurement; and amniotic fluid volume ◆ Detailed re-examination of a specific organ or system known or suspected to be abnormal ◆ (there is no interval requirement when ordered as follow-up for an indeterminate anatomy scan)
---------------	--

References

1. Wax J, Minkoff H, Johnson A, et al. Consensus Report on the Detailed Fetal Anatomic Ultrasound Examination. *Journal of Ultrasound in Medicine*. 2014;33(2):189-195. doi:10.7863/ultra.33.2.189.
2. Practice Bulletin No. 175 Summary. *Obstetrics & Gynecology*. 2016;128(6):1459-1460. doi:10.1097/aog.0000000000001812.
3. Wax J, Minkoff H, Johnson A, et al. Consensus Report on the Detailed Fetal Anatomic Ultrasound Examination. *Journal of Ultrasound in Medicine*. 2014;33(2):189-195. doi:10.7863/ultra.33.2.189.
4. Berghella V. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. *American Journal of Obstetrics and Gynecology*. 2012;206(5):376-386. doi:10.1016/j.ajog.2012.03.010.
5. American Medical Association. CPT—Current Procedural Terminology. Accessed November 15, 2017. <https://www.ama-assn.org/practice-management/cpt-current-procedural-terminology>.
6. Practice Bulletin No. 130. *Obstetrics & Gynecology*. 2012;120(4):964-973. doi:10.1097/aog.0b013e3182723b1b. reaffirmed 2016.
7. Cho HJ, Roh H-J. Correlation Between Cervical Lengths Measured by Transabdominal and Transvaginal Sonography for Predicting Preterm Birth. *Journal of Ultrasound in Medicine*. 2016;35(3):537-544. doi:10.7863/ultra.15.03026.
8. McIntosh J, Feltovich H, Berghella V, Manuck T. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. *American Journal of Obstetrics and Gynecology*. 2016;215(3). doi:10.1016/j.ajog.2016.04.027.
9. Khalifeh A, Berghella V. Not transabdominal! *American Journal of Obstetrics and Gynecology*. 2016;215(6). doi:10.1016/j.ajog.2016.07.019.
10. Esplin MS, Elovitz MA, Iams JD, et al. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. *Jama*. 2017;317(10):1047. doi:10.1001/jama.2017.1373.
11. Jain S, Kilgore M, Edwards RK, Owen J. Revisiting the cost-effectiveness of universal cervical length screening: importance of progesterone efficacy. *American Journal of Obstetrics and Gynecology*. 2016;215(1). doi:10.1016/j.ajog.2016.01.165.

OB-6: No Fetal Heart Tone/Decreased Fetal Movement

OB-6.1: No Fetal Heart Tone/Decreased Fetal Movement

24

OB-6.1: No Fetal Heart Tone/Decreased Fetal Movement

- Ultrasound is appropriate to confirm suspected fetal demise

The following is supported during the first trimester:

- Prior to considering ultrasound for absence of fetal heart tone at less than 12 weeks, fetal heart tone assessment should be repeated at 12 weeks gestation
- Ultrasound imaging is supported, prior to 12 weeks gestation, in the setting of absent fetal heart tones accompanied by other maternal signs or symptoms (such as cramping, vaginal bleeding, etc.) or if fetal heart tones that have previously been heard are now unable to ascertain, regardless of symptoms. Report **one** of the following:
 - ◆ CPT® 76801 (plus CPT® 76802 if more than one fetus) and/or CPT® 76817 if a complete ultrasound has not yet been performed; or
 - ◆ CPT® 76815 for limited ultrasound and/or CPT® 76817

The following is supported during the second and third trimester:

- If less than 24 weeks gestation, report **one** of the following:
 - ◆ CPT® 76805 if a complete fetal anatomic scan is planned and has not yet been performed during this pregnancy (plus CPT® 76810 if more than one fetus); **or**
 - ◆ CPT® 76816 if a complete ultrasound was done previously; **or**
 - ◆ CPT® 76815 for limited ultrasound; **and/or**
 - ◆ CPT® 76817 for a transvaginal ultrasound
- If pregnancy is greater than or equal to 24 weeks, initial evaluation is usually done with: (CPT® 76815) to document fetal heart activity **or** BPP (CPT® 76818 or CPT® 76819). No further imaging is necessary if:
 - ◆ NST is reactive and AFI is normal **or**
 - ◆ CST is negative
- If NST is non-reactive or CST is positive:
 - ◆ CPT® 76805 if a complete fetal anatomic scan is planned and has not yet been performed during this pregnancy (plus CPT® 76810 if more than one fetus) **or**
 - ◆ CPT® 76816 if a complete ultrasound was done previously **or**
 - ◆ CPT® 76815 for limited ultrasound

Reference

1. Practice Bulletin No. 145. Obstetrics & Gynecology. 2014;124(1):182-192. doi:10.1097/01.aog.0000451759.90082.7b.

OB-7: Fetal Echocardiography (ECHO)

OB-7.1: Indications for Fetal Conditions	26
OB-7.2: Indications for Maternal Conditions	27

OB-7.1: Indications for Fetal Conditions

- The minimal use of color Doppler alone, when performed for anatomical structure identification during a standard ultrasound procedure, is not separately reimbursable.

➤ Fetal echocardiography (Initial study-CPT® 76825 or follow-up-CPT® 76826) (follow-up echo must go to MD review)
➤ Doppler echocardiography (Initial study-CPT® 76827 or follow-up-CPT® 76828) (repeat echo must go to MD review) and
➤ Doppler color flow velocity mapping (CPT® 93325) can be ordered together or separately for the following conditions:
➤ Transabdominal fetal echo is usually not performed prior to 16 weeks
➤ Abnormal or suspected abnormal fetal cardiac evaluation on fetal anatomic scan. ◆ There must be documentation (provided as hard copy or acknowledged verbally by provider) that the four chamber cardiac study was abnormal or suspected abnormal on the anatomic scan in order for fetal echo to be indicated
➤ If a heart abnormality is found, a fetal ECHO (CPT® 76825 and/or CPT® 76827) may be approved for preparation of delivery
➤ Suspected or known fetal arrhythmia (to define the rhythm and assess for possible structural cardiac anomalies)
➤ Known fetal extra-cardiac anomaly, excluding cardiac echogenic foci and choroid plexus cyst see: OB-11.2.b: High Risk Group Two b
➤ Congenital heart disease (CHD) or cardiac anomaly in a 1 st degree relative of the fetus (maternal, paternal, or sibling)
➤ As a screening study typically performed at <u>22 to 26 weeks gestation</u> (may be performed earlier if anomaly is suspected on prior ultrasound) ◆ if maternal non-diet-controlled diabetes is present (See: OB-11:High Risk Pregnancy)
➤ Known fetal chromosomal abnormalities (fetal aneuploidy) or ultrasound findings of a suspected chromosomal abnormality.
➤ Single umbilical artery (two vessel cord), abnormality of umbilical cord, placenta or intraabdominal venous anomaly (persistent right umbilical vein)
➤ Fetal hydrops see: OB-3: Alloimmunization/Rh Isoimmunization/Other Causes of Fetal Anemia/Parvo/Hydrops
➤ Monochorionic twins/TTTS
➤ IVF pregnancies
➤ Exposure of fetus to: ◆ Lithium ◆ Excessive alcohol ◆ Anti-seizure medication, e.g. hydantoin ◆ Paroxetine ◆ Birth control pills ◆ Ace inhibitors ◆ Folate antagonists (methotrexate) ◆ Anticonvulsants ◆ Retinoic acid ◆ Thalidomide ◆ Amphetamines ◆ Cocaine ◆ NSAIDS (Ibuprofen, Indomethacin) 2nd and 3rd trimester ◆ Vitamin A greater than 10,000 units per day ◆ Opiates ◆ Benzodiazepines ◆ Other teratogen exposure to the fetus with a known association for cardiac anomalies

- Abnormal Fetal Nuchal Translucency scan ($\geq 3.0\text{mm}$) during current pregnancy.
 - ◆ Can also perform CPT® 76811 if not previously performed or if patient is being referred to another specialist (MFM/Perinatologist or Radiologist) for a second opinion.
- Polyhydramnios

OB-7.2: Indications for Maternal Conditions

For Maternal Conditions:

- All diabetes except gestational diabetes mellitus not on medication unless HbA1C is $> 6.5\%$ Connective tissue diseases (SLE [Lupus], Sjogrens, RA, Scleroderma etc.) with Anti-Ro/SSA or anti-La/SSB antibodies present
- Rubella infection
- Phenylketonuria
- Presence of other maternal conditions associated with cardiac anomalies (such as parvovirus, CMV, Coxsackie virus, Toxoplasmosis)
- Family history of a first degree relative to the fetus with a congenital heart defect or genetic conditions associated with CHD (such as family history of Marfan syndrome or Noonan syndrome)
- Seizure disorder

Coding Notes

- Requests for repeat fetal echo will be forwarded to Medical Director review
- CPT® 76825 and CPT® 76827 are performed only once per fetus
- Follow-up echocardiograms are reported as CPT® 76826
- Follow-up Doppler fetal echocardiograms are reported as CPT® 76828
- If a Fetal Echo is ordered for an individual who has not had a previous echo in the pregnancy, and the clinical criteria are met, then the Fetal Echo may be approved using the following CPT® codes for the initial echo:
- CPT® 76825 and/or CPT® 76827 and/or CPT® 93325 (add on code for color mapping)
- Requests for follow-up studies CPT® 76826 and/or CPT® 76828 (limited/follow-up study) will be forwarded to Medical Director for review.

Practice Note

There are no formal guidelines for the type or the frequency of testing to detect fetal heart block, but performing weekly pulsed Doppler fetal echocardiography (CPT® 76828) from the 18th through the 26th week of pregnancy and then every other week until 32 weeks should be strongly considered. The most vulnerable period for the fetus is during the period from 18 to 24 weeks gestation. Normal sinus rhythm can progress to complete block in seven days during this high-risk period. New onset of heart block is less likely during the 26th through the 30th week, and it rarely develops after 30 weeks of pregnancy.

References

1. Donofrio MT, Moon-Grady AJ, Hornberger LK et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. *Circulation*. 2014;129(21):2183-242. Accessed November 15, 2017. <https://www.medscape.com/medline/abstract/24763516>.
2. Gewillig M, Brown SC, De Catta L, et al. Premature foetal closure of the arterial duct: clinical presentations and outcome. *Eur Heart J* 2009;30(12):1530-1536. Accessed November 15, 2017. <http://www.pcssa.org/test/wp-content/uploads/2013/12/Premature-foetal-closure-of-the-arterial.pdf>.
3. Brucato A. Prevention of congenital heart block in children of SSA-positive mothers. *Rheumatology*. 2008;47(3):iii35-iii37. Accessed November 15, 2017. <https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ken153>.
4. Clur SA, Ottenkamp, and Bilardo CM. The nuchal translucency and the fetal heart: a literature review. *Prenat Diagn*. 2009;29(8):739-48. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/pd.2281/epdf>.

OB-8: Fetal Growth Problems

OB-8.1: Fetal Growth Restriction Current Pregnancy	30
OB-8.2: Macrosomia-Large for Dates Current Pregnancy	31

OB-8.1: Fetal Growth Restriction Current Pregnancy

- The ACOG definition of Fetal Growth Restriction (FGR): Estimated or actual weight of the fetus $\leq 10^{\text{th}}$ percentile for gestational age. “Abdominal Circumference $\leq 10^{\text{th}}$ percentile” also defines FGR.

For Suspected FGR:

- One ultrasound can be performed if there is more than a 3 week difference in fundal height and gestational age report **one** of the following:
 - ◆ CPT® 76805 (plus CPT® 76810 if more than one fetus) if a complete ultrasound has not yet been performed during this pregnancy **or**
 - ◆ CPT® 76816 if a complete ultrasound was performed previously
- In order to evaluate fetal growth and confirm the diagnosis of FGR following the initial ultrasound, one follow-up ultrasound (CPT® 76816) can be performed 2 to 4 weeks following the initial ultrasound
- For clinical situations that have a higher probability of FGR such as maternal hypertension, maternal diabetes, previous stillbirth, etc. See: **OB-11: High Risk Pregnancy**, or the specific guidelines for these clinical entities for guidance regarding follow-up ultrasounds to assess fetal growth

For Known FGR:

- Detailed Fetal Anatomic Scan (CPT® 76811) upon diagnosis if not already performed
- Ultrasound (CPT® 76816) every 2 to 4 weeks to assess fetal growth starting at 23 to 24 weeks
- Starting at 23 to 24 weeks, weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST
- Starting at 23 to 24 weeks, weekly umbilical artery Doppler (CPT® 76820); if umbilical artery dopplers are abnormal, then more frequent BPPs (CPT® 76818 or CPT® 76819) may be considered (2x per week, or even daily)
- MCA Doppler (CPT® 76821) start at 34 weeks, weekly if the doppler CPT® 76820 is normal

Practice Notes

- In the preterm SGA/FGR fetus, middle cerebral artery (MCA) Doppler has limited accuracy to predict acidemia and adverse outcome; it should not be used to time delivery. Most studies investigating MCA Doppler as a predictor of adverse outcome in preterm SGA/FGR fetuses have reported low predictive value, especially when umbilical artery Doppler is abnormal. In the largest study of predictors of neonatal outcome in SGA/FGR neonates of less than 33 weeks gestational age (n = 604), it was not a statistically significant predictor of outcome on logistic regression, although MCA PI < -2 SDs was associated with neonatal death (LR 1.12, 95% CI 1.04–1.21) and major morbidity (LR 1.12, 95% CI 1.1–1.33).
- In addition it has been found that umbilical artery Doppler studies are less reliable after 34 weeks as IUGR at 34 weeks or greater is typically characterized by milder placental dysfunction.

- In the near-term SGA/FGR fetus with normal umbilical artery Doppler, an abnormal middle cerebral artery Doppler (PI <5th centile) has moderate predictive value for acidosis at birth and should be used to time delivery. MCA Doppler may be a more useful test in SGA/FGR fetuses detected after 34 weeks of gestation when umbilical artery Doppler is normal. Based on this evidence it is reasonable to use MCA Doppler to time delivery in the near term-term (34 weeks gestation or greater) SGA/FGR fetus with normal umbilical artery Doppler.

OB-8.2: Macrosomia-Large for Dates Current Pregnancy

- The ACOG definition of macrosomia: Estimated fetal weight of greater than 4000 grams (DM) or 4500 grams (non-DM); $\geq 90^{\text{th}}$ percentile or greater for gestational age
- See also: **OB-11.4.a: Prior Pregnancy with Macrosomia**

For Suspected Macrosomia:	
➤	In a low risk pregnancy, ultrasound is generally not indicated to estimate fetal weight before 30 weeks gestation
➤	At 30 weeks gestation or greater, if there is more than a 3 week difference in fundal height and gestational age, one ultrasound can be performed to evaluate for macrosomia if clinically indicated report one of the following: ◆ CPT® 76805 [plus CPT® 76810 if more than one fetus] if a complete fetal anatomic scan is planned and has not yet been performed or ◆ CPT® 76816 if a complete ultrasound was done previously
➤	See also: <u>OB-22.1: Unequal Fundal Size and Dates</u>
For Known Macrosomia $\geq 90^{\text{th}}$ percentile	
➤	Repeat imaging is generally not necessary unless needed to plan for delivery or if there are other high risk indications. At > 30 weeks gestation, (CPT®76816) every 2 to 4 weeks only if other high risk indication(s) are present ◆ Imaging recommendations are usually guided by the cause of the fetal macrosomia (obesity, DM, etc.) See appropriate GL for indication
➤	If no other high risk indication present, one CPT® 76816 at 37 weeks to plan for delivery

Practice Notes

Ultrasound is imprecise in predicting fetal macrosomia. Prospective studies have shown that clinical estimates of macrosomia may be as predictive as estimates derived by ultrasonography

References

1. ACOG Practice Bulletin No. 134: Fetal Growth Restriction. Reaffirmed 2018, Obstet Gynecol. 2013 May;121(5):1122-1133. Accessed July 2, 2018.
https://journals.lww.com/greenjournal/Abstract/2013/05000/Practice_Bulletin_No_134_Fetal_Growth.45.aspx.
2. ACOG Practice Bulletin No. 173, November 2016 (Replaces Practice Bulletin Number 22, November 2000) Fetal Macrosomia. Obstet Gynecol. 2013; reaffirmed 2015;128(5):e195-e209. Accessed July 2, 2018.
https://journals.lww.com/greenjournal/Abstract/2016/11000/Practice_Bulletin_No_173_Fetal_Macrosomia.51.aspx.
3. Copel JA and Bahtiyar MO. A practical approach to fetal growth restriction. ObstetGynecol. 2014;123(5):1057-1069. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Abstract/2014/05000/A_Practical_Approach_to_Fetal_Growth_Restriction.22.aspx.
4. Oros D, Figueras F, Cruz-Martinez R, et al. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2011 Feb;37(2):191–195. Accessed January 30, 2018.
<https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1002/uog.7738>.
5. Cohen E, Baerts W, and van Bel F. Brain-Sparing in intrauterine growth restriction: considerations for the neonatologist. Neonatology. 2015;108:269-276. Accessed November 15, 2017.
<https://www.karger.com/Article/Pdf/438451>.
6. Practice Bulletin 145: Antepartum surveillance 2016. Obstetrics and Gynecology. 2014;124(1):182-192, reaffirmed in 2016. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2014/07000/Practice_Bulletin_No_145_Antepartum_Fetal.35.aspx.
7. Wax J, Minkoff H, Johnson A et al. Consensus report on the detailed fetal anatomic ultrasound examination indications, components, and qualifications. J Ultrasound Med. 2014;33(2):189-195. Accessed November 15, 2017.
http://api.ning.com/files/cZ399qCqOaHeuZzVLVyhlBxiUetrLyKO3Bw9Tt6vH2VZjNDiuNoRV*TfNUrqT5k4qdLfS6J8OIAGmAHfkKiXIDZdpW4U1-u/consensus768112014.pdf.

OB-9: Placental or Cord Abnormalities

OB-9.1: Vasa Previa	34
OB-9.2: Placental or Cord Abnormalities	34
OB-9.3: Subchorionic Hematoma or Placental Hematoma	34
OB-9.4: Suspected Abruption Placentae	35
OB-9.5: Placenta Previa	35
OB-9.6: Placenta Accreta/Placenta Percreta	36
OB-9.6.a: Suspected	36
OB-9.6.b: Known	36

OB-9.1: Vasa Previa

- Vasa previa occurs when fetal blood vessels that are unprotected by the umbilical cord or placenta run through the amniotic membranes and cross over the internal cervical os. Vasa previa can occur when there is a velamentous cord insertion, or with a succenturiate or multilobed placenta.
- Ultrasound (CPT® 76817 and/or CPT® 76815 or CPT® 76816) every 2 to 4 weeks to assess cervical length starting at 28 weeks. If earlier, requests will be sent to Medical Director review.
- Amniocentesis is no longer required or recommended for lung maturity.

OB-9.2: Placental or Cord Abnormalities

- For the following conditions, ultrasound (CPT® 76817 and/or CPT® 76815 or CPT® 76816) every 2 to 4 weeks starting at 28 weeks until delivery and weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST starting at 32 weeks. If earlier, requests will be sent for Medical Director review.
 - ◆ Placental infarction
 - ◆ Circumvallate shape
 - ◆ Placental hemangioma
 - ◆ Succenturiate placenta or accessory lobe
 - ◆ Chorioangioma
 - ◆ Marginal Cord Insertion
 - ◆ Velamentous insertion of the umbilical cord
 - ◆ Umbilical cord varix
 - ◆ Umbilical cord cyst

OB-9.3: Subchorionic Hematoma or Placental Hematoma

Subchorionic Hematoma or Placental Hematoma	
First, Second and Third Trimester	
➤	Ultrasound can be performed for follow-up of a known subchorionic hematoma or placental hematoma (CPT® 76815, or CPT® 76816 if a complete fetal anatomic scan was done previously, and/or CPT® 76817) if the last ultrasound was performed greater than seven days ago.
➤	Ultrasound imaging may be repeated earlier than seven days if there are new or worsening symptoms such as an increasing amount of vaginal bleeding or increasing cramping or pain.
➤	No further ultrasound is needed if the follow-up ultrasound 7 days following the hemorrhage shows that the hemorrhage has resolved, and there is no further cramping and/or bleeding, and the fetus is growing as determined by size equal dates, in the first trimester.
➤	If pregnancy is in second or third trimester follow <u>OB-9.4: Suspected Abruption Placentae</u>

OB-9.4: Suspected Abruption Placentae

Suspected Abruption Placentae
Second and Third Trimesters
➤ Ultrasound is appropriate for suspected abruption placentae CPT® 76805 [plus CPT® 76810 if more than one fetus] and/or CPT® 76817 if a complete fetal anatomic scan has not yet been performed during this pregnancy, or ◆ CPT® 76815 for limited ultrasound and/or CPT® 76817, or ◆ CPT® 76816 if a complete fetal anatomic scan was done previously, and/or CPT® 76817 for a transvaginal ultrasound ➤ Ultrasound is appropriate to follow-up a known abruption (CPT® 76815 or CPT® 76816 and/or CPT® 76817). ◆ The number and frequency of follow-up ultrasounds will depend on the degree of abruption and the presence or absence of ongoing signs and symptoms

OB-9.5: Placenta Previa

Placenta Previa
Second and Third Trimesters
➤ For suspected placenta previa ultrasound can be performed (CPT® 76805 [plus CPT® 76810 if more than one fetus] (and/or CPT® 76817) if a complete fetal anatomic scan has not yet been performed during this pregnancy or ◆ CPT® 76815 for limited ultrasound and/or CPT® 76817 or ◆ CPT® 76816 if a complete fetal anatomic scan was done previously and/or ◆ CPT® 76817 for a transvaginal ultrasound) ➤ For known placenta previa, one routine follow-up ultrasound can be performed at 28 to 32 weeks (CPT® 76815 or CPT® 76816 and/or CPT® 76817) ◆ If placenta previa is still present, one follow-up ultrasound (CPT® 76815 or CPT® 76816 and/or CPT® 76817) can be performed at 35 to 37 weeks. Amniocentesis is no longer required or recommended for lung maturity ◆ If persistent placenta previa, BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST weekly, starting at 32 weeks ◆ Follow-up ultrasound can be performed at any time if bleeding occurs BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 or CPT® 76816 and/or CPT® 76817)

Practice Note

“For pregnancies beyond 16 weeks, if the placental edge is 2 cm or greater away from the internal os, the placental location should be reported as normal.

If the placental edge is less than 2 cm from the internal os but not covering the internal os, it should be labeled as low lying, and a follow-up ultrasound examination is recommended at 32 weeks' gestation.

If the placental edge covers the internal cervical os, the placenta should be labeled as a placenta previa, and a follow-up ultrasound examination is recommended at 32 weeks' gestation.

At the follow-up examination at 32 weeks, if the placental edge is still less than 2 cm from the internal os (low lying) or covering the cervical os (placenta previa), follow-up transvaginal imaging at 36 weeks' gestation is recommended."

American Institute of Ultrasound in Medicine (AIUM). Practice Parameter for the Performance of Limited Obstetric Ultrasound Examinations by Advanced Clinical Providers. J Ultrasound Med 2018; 37:1587–1596.

OB-9.6: Placenta Accreta/Placenta Percreta

OB-9.6.a: Suspected

- For **suspected** placenta accreta, ultrasound can be performed (CPT® 76805 [plus CPT® 76810 if more than one fetus] (and/or CPT® 76817) if a complete fetal anatomic scan has not yet been performed **or**
 - ◆ CPT® 76815 for limited ultrasound and/or, CPT® 76817, **or**
 - ◆ CPT® 76816 if a complete fetal anatomic scan was done previously, **and/or** CPT® 76817 for a transvaginal ultrasound)
- If the ultrasound is inconclusive or equivocal, send to MD review

OB-9.6.b: Known

- For **known** placenta accrete/percreta, follow up growth ultrasounds can be performed every 2 to 4 weeks (CPT® 76816 and/or CPT® 76817)
- BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST weekly, starting at 32 weeks or sooner if indicated (other high-risk concerns)
- Follow-up ultrasound can be performed at any time if bleeding occurs (CPT® 76815 and/or CPT® 76817)
- MD can approve Pelvic MRI without contrast (CPT® 72195) if the ultrasound is indeterminate or advanced imaging is needed for surgical planning. MRI pelvis without contrast (CPT® 72195) is the appropriate code if only placenta or maternal pelvis is imaged without fetal imaging

Practice Note

When there are ambiguous ultrasound findings or suspicion of a posterior placenta accreta, with or without placenta previa, ultrasound may be insufficient. MRI is able to outline the anatomy of the invasion and relate it to the regional anastomotic vascular system and enable confirmation of parametrial invasion and possible ureteral involvement.

References

1. Committee Opinion No. 560: Medically indicated late-preterm and early-term deliveries. Obstet Gynecol. 2013 May;121(4):908-910. reaffirmed 2017. Accessed November 3, 2017. http://journals.lww.com/greenjournal/Fulltext/2013/04000/Committee_Opinion_No_560_Medically_Indicated.45.aspx.
2. Practice Bulletin 134: Fetal Growth Restriction. Obstet Gynecol. 2013, reaffirmed 2018; 121(5):1122-1133. Accessed November 15, 2017. https://journals.lww.com/greenjournal/Abstract/2013/05000/Practice_Bulletin_No_134_Fetal_Growth.45.aspx.
3. Committee Opinion No. 529: Placenta accrete. Obstet Gynecol. 2012;120:207–11, reaffirmed 2017. Reaffirmed 2017 Accessed November 3, 2017. https://journals.lww.com/greenjournal/Citation/2012/07000/Committee_Opinion_No_529_Placenta_Accreta.42.aspx.
4. Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, et al. MRI of placenta accreta, placenta increta, and placenta percreta: pearls and pitfalls. Am J Roentgenol. 2017 Jan;208(1):214-221. Accessed January 30, 2018. <https://www.ajronline.org/doi/full/10.2214/AJR.16.16281>.
5. Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol. 2017 October;130:e210-6. Accessed August 10, 2018. https://journals.lww.com/greenjournal/fulltext/2017/10000/Committee_Opinion_No_723_Guidelines_for.60.aspx.
6. Society for Maternal-Fetal Medicine (SMFM) Consult Series #37: Diagnosis and management of vasa previa. Society of Maternal-Fetal (SMFM) Publications Committee; Rachel G. Sinkey, MD; Anthony O. Odibo, MD, MSCE; Jodi S. Dashe, MD. Accessed August 13, 2018. [https://www.ajog.org/article/S0002-9378\(15\)00897-2/fulltext](https://www.ajog.org/article/S0002-9378(15)00897-2/fulltext).
7. Abnormal Placentation. Placenta Previa, Vasa Previa, and Placenta Accreta. Robert M. Silver, MD. Obstet Gynecol 2015;126:654–68. Accessed August 10, 2018. https://journals.lww.com/greenjournal/Abstract/2015/09000/Abnormal_Placentation_Placenta_Previa_Vasa.30.aspx.
8. American Institute of Ultrasound in Medicine (AIUM). AIUM Practice Parameter for the Performance of Limited Obstetric Ultrasound Examinations by Advanced Clinical Providers. J Ultrasound Med 2018; 37:1587–1596. Accessed August 13, 2018. https://www.aium.org/resources/guidelines/LimitedOB_Providers.pdf.

OB-10: Fetal Aneuploidy and Anomaly Screening

OB-10.1: First Trimester Screening	39
OB-10.2: Second Trimester Screening	40

OB-10.1: First Trimester Screening

- First trimester nuchal translucency is not necessary if cfDNA is done
 - ◆ First trimester screening includes biochemical markers and fetal nuchal translucency (FNT) (CPT® 76813). Conducted together, these screenings can identify risk for specific chromosomal abnormalities (e.g. Down's syndrome, Trisomy-18)
 - ◆ Nuchal translucency is completed between 11 and 13 6/7 weeks (CRL between 44 and 83 mm) but can be performed if the crown rump length (CRL) measures between 44-83mm regardless of gestational age. An abnormal Fetal Nuchal Translucency scan, with a nuchal translucency measurement of ≥ 3.0 mm, may indicate an increased risk for cardiac defects, abdominal wall defects, diaphragmatic hernia, and genetic syndromes in euploid fetuses; whereas, a nuchal translucency ≥ 2.5 mm may indicate an increased risk for aneuploidy (imaging should be based upon the MOM for NT and biochemical markers).
 - ◆ "... the use of ultrasound codes CPT® 76801/ CPT® 76802 should be indication driven and should not be routinely done whenever an ultrasound for nuchal translucency (CPT® 76813/ CPT® 76814) is requested. In cases where there is either a maternal and/or fetal indication then the CPT® 76801 code can indeed be billed along with the nuchal translucency screening (CPT® 76813/ CPT® 76814)." (Society for Maternal-Fetal Medicine)

First Trimester Screening:

- Ultrasound is the initial imaging for the first trimester screening, to evaluate fetal nuchal translucency
- If the nuchal translucency is abnormal (≥ 2.5 mm), the following tests can be performed:
 - ◆ Fetal anatomic ultrasound (CPT® 76811) at 16 weeks or greater
 - ◆ Amniocentesis
 - ◆ CVS
 - ◆ Fetal echocardiogram (NT ≥ 3.0 mm)
- Abnormal FNT with normal aneuploidy screen and normal chromosomes (as measured by chorionic villus sampling or amniocentesis) should be evaluated with a fetal echo (CPT® 76825 and/or CPT® 76827 and/or CPT® 93325) and fetal ultrasound (CPT® 76811)

Coding Notes

- CPT® 76813 and CPT® 76814 should be performed only by those certified by the Fetal Medicine Foundation or Nuchal Translucency Quality Review Program (NTQR)
- Report as CPT® 76813 (plus CPT® 76814 if more than one fetus)
- CPT® 76813 can be performed once per pregnancy if the pregnancy is 11 to 13 6/7 weeks (44mm – 83mm) but can be performed if the CRL measures between 44-83mm regardless of gestational age
- If FNT is abnormal, CPT® 76811 is usually performed by a Maternal Fetal Medicine (MFM)/Perinatologist, Radiologist, or facility/physician with AIUM certification (with advanced training in fetal imaging) after 16 weeks

- The use of ultrasound codes (CPT® 76801/CPT® 76802) should be indication driven and should not be routinely done whenever an ultrasound for nuchal translucency (CPT® 76813/CPT® 76814) is requested. In cases where there is either a maternal and/or fetal indication, then the CPT® 76801 code can indeed be billed along with the nuchal translucency screening (CPT® 76813/CPT® 76814)

OB-10.2: Second Trimester Screening

See also: **OB-5.1: Initial Screening for Fetal Anomalies**

Two studies, a quad screen and ultrasound, are done during the second trimester to detect fetal aneuploidy, neural tube defects, and other anatomical defects.

- A fetal anatomic scan to screen for anomalies is ideally performed at 18 to 20 weeks but may be performed after week ≥ 16. If less than 16 weeks, send to MD review
- If the quad screening is abnormal, an ultrasound (CPT® 76811) may also be performed

Practice Notes

Multiple marker screening is used in the second trimester (15 to 20 weeks) to screen for trisomies 21 and 18 as well as open neural tube defects (ONTD).

The “quad” screen is the most commonly used test for the second trimester.

The quad screen measures four substances:

1. AFP (alpha-fetoprotein)
2. hCG (human chorionic gonadotropin)
3. uE (Unconjugated estriol)
4. dimeric inhibin-A

A penta screen may be done in lieu of a quad screen, the penta screen includes hyperglycosylated hCG in addition to the quad screen markers.

The “penta” screen measures five substances:

1. AFP
2. hCG
3. hyperglycosylated hCG
4. uE
5. dimeric inhibin-A

Maternal serum alpha-fetoprotein (MSAFP) can be done at 15 to 20 weeks to screen for neural tube defects if quad or penta is not performed. (Those that have had cfDNA or NT screen will need MSAFP tested separately in the mid-trimester to screen for open neural tube defect).

Combined, integrated or sequential screening (first and second trimester screening) may also be used and provides a higher detection rate than a single screening.

Providers often wait for the results of the quad screen before ordering CPT® 76805. If the quad screen is abnormal, they may request CPT® 76811 in lieu of CPT® 76805.

Cell-Free DNA Testing-cfDNA

First trimester nuchal translucency screening is not necessary if cfDNA is performed as they are both screenings for fetal aneuploidy.

Cell-free fetal DNA (cfDNA) has been noted to be the most sensitive test for Down syndrome per the American College of Medical Genetics and Genomics.

Testing can be offered as early as the 10th week of pregnancy.

With a negative cfDNA test, it is very unlikely the fetus has trisomy 21, 13 or 18. Other chromosomal abnormalities may also be identified. The sex and Rh status of the baby may be included. The American College of Medical Genetics and Genomics (ACMG) recommends against using this test to screen for microdeletions or any autosomal aneuploidies other than 13, 18 and 21.

A woman with a positive cfDNA should be offered diagnostic testing (amniocentesis or CVS). A detailed anatomy scan 76811 is indicated at 16 weeks or greater. See: **OB-11.1: High Risk Group One-Risk Factors**.

A “no call” or indeterminate result can occur (risk is higher with maternal obesity), but this has a higher risk of chromosomal abnormality than a normal result. The patient should be offered amniocentesis or CVS testing.

Note that cfDNA does not screen for neural tube defects. Patients should be offered screening for open neural tube defects with maternal serum AFP (MSAFP) or ultrasound (usual anatomy scan- CPT® 76805 or CPT® 76811 depending on risk factors)

References

1. Practice Bulletin: No.187: Neural Tube Defects. Obstet Gynecol. 2017 Dec;130(6):e279-e290. Accessed January 30, 2018.
https://journals.lww.com/greenjournal/Abstract/2017/12000/Practice_Bulletin_No_187_Neural_Tube_Defects.41.aspx.
2. Society for Maternal and Fetal Medicine (SMFM), coding committee, October 2017. SMFM's white paper on billing combination of 76801 and 76813.
3. Practice Bulletin No.162: Prenatal diagnostic testing for genetic disorders. Obstet Gynecol. 2016 May; 127(5):e108-e122. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2016/05000/Practice_Bulletin_No_2_Prenatal_Diagnostic.40.aspx.
4. Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet Gynecol. 2016 May;127(5):e123-e137. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Abstract/2016/05000/Practice_Bulletin_No_163_Screening_for_Fetal.41.aspx.
5. Practice Bulletin No. 175: Ultrasound in pregnancy. 2016 Dec;128(6):e241-e256. Accessed November 15, 2017.
<http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2016&issue=12000&article=00053&type=Fulltext>.
6. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy 2016 update: a position statement of the ACMGG. American College of Medical Genetics and Genomics. Accessed August 13, 2018. <https://www.nature.com/articles/gim201697>.
7. AJOG/SMFM: Consult series number 42. The role of ultrasound in women who undergo cell-free DNA screening. 2017; 216(3)B2-B7. Accessed November 15, 2017.
<https://www.sciencedirect.com/science/article/pii/S0002937817301059>.
8. Donofrio MT, Moon-Grady AJ, Hornberger LK et al. Diagnosis and treatment of fetal cardiac disease: A scientific statement from the American Heart Association. Circulation, 2014;129(21):2183-242. Accessed August 13, 2018.
<https://www.ahajournals.org/doi/pdf/10.1161/01.cir.0000437597.44550.5d>.
9. SMFM Coding Committee White Paper: Billing of 76801 and/or 76813 with cfDNA screening. Publications & Guidelines | SMFM.org - The Society for Maternal-Fetal Medicine. <https://www.smfm.org/>. Published October 2017. Accessed September 5, 2018

OB-11: High Risk Pregnancy

OB-11.01: High Risk Pregnancy Special Considerations	44
OB-11.1: High Risk Group One-Risk Factors	44
OB-11.1.a: Socio-Demographic Risk Factors sk Factors	44
OB-11.1.b: Lifestyle Related Risk Factors	44
OB-11.1.c: Health Condition Related Risk Factors	44
OB-11.1.d: Previous pregnancy related risk factors	45
OB-11.1.e: Current pregnancy related risk factors	45
OB-11.1.f: Maternal Infections	45
OB-11.1.g: Imaging For Above Conditions	46
OB-11.2: High Risk Group Two – Findings on Ultrasound That May Require Further Imaging	46
OB-11.2.a: High Risk Group Two a.	46
OB-11.2.b: High Risk Group Two b.	46
OB-11.3: High Risk Group Three – BMI	47
OB-11.3.a: Pre-pregnancy BMI 30 to 34	47
OB-11.3.b: Pre-pregnancy BMI 35-39	47
OB-11.3.c: Pre-pregnancy BMI $\geq$ 40	47
OB-11.4: High Risk Group Four	48
OB-11.4.a: Prior Pregnancy with Macrosomia	48
OB-11.4.b: Current Pregnancy with Suspected or Known Macrosomia	48
OB-11.5: High Risk Group Five: Zika Virus	49
OB-11.6: High Risk Group 6- Pre-Gestational Diabetes on Oral Medications or Insulin	49
OB-11.7: High Risk Group Seven Gestational Diabetes	51
OB-11.7.a: Gestational Diet Controlled	51
OB-11.7.b: Gestational Diabetes on Oral Medications or Insulin	52
OB-11.8: Hypertension	53
OB-11.9: Single Umbilical Artery	54
OB-11.10 History of Pre-Term Delivery/History of PPROM	54
OB-11.10.a Preterm Delivery $\leq$ 34 Weeks History of PPROM $\leq$ 34 weeks	54
OB-11.10.b: History of Preterm Delivery $>$ 34 weeks	54
OB-11.11: History of Stillbirth	55

OB-11.01: High Risk Pregnancy Special Considerations

For the following conditions, please follow the links for appropriate imaging:

- Abnormal nuchal translucency - thickened nuchal fold ≥ 5 mm at 16 to 20 weeks or ≥ 6 mm at 20 to 22 weeks (if CPT® 76811 shows adequate heart views, then no indication for echo) See: **OB-10.1: First Trimester Screening**
- Fetal Growth Restriction and Macrosomia see: **OB-8: Fetal Growth Problems**
- History of late fetal death (greater than or equal to 20 weeks) See: **OB-11.11: History of Stillbirth**
- History of Prior C-section See: **OB-17: Previous C-section or History of Uterine Scar**
- Multiple Gestations see: **OB-16: Multiple Pregnancies**
- Oligohydramnios or polyhydramnios see: **OB-4: Amniotic Fluid Abnormalities/Oligohydramnios/Polyhydramnios**
- Premature rupture of membranes (PROM) See: **OB-19.1: Current Preterm Prelabor Rupture of Membranes (PPROM)**
- Rh sensitization/isoimmunization See: **OB-3: Alloimmunization/Rh Isoimmunization. Other Causes of Fetal Anemia/Parvo/Hydrops**
- Vasa previa/placenta accrete/placental abnormalities see: **OB-9: Placental or Cord Abnormalities**

OB-11.1: High Risk Group One-Risk Factors

HIGH RISK PREGNANCY – Risk Factors	
OB-11.1.a: Socio-Demographic Risk Factors	
➤	Age greater than or equal to 35 years of age at the estimated date of confinement (EDC)
OB-11.1.b: Lifestyle Related Risk Factors	
➤	Recreational drug or alcohol use during current pregnancy (excluding marijuana) See: <u>OB-25: High Risk Medications and Substances</u>
➤	10 or more cigarettes a day (1/2 pack a day)
➤	Maternal history of IV drug abuse
OB-11.1.c: Health Condition Related Risk Factors	
➤	Anemia severe, less than 8 grams Hgb or 24% HCT
➤	Antiphospholipid Syndrome/Autoimmune disease
➤	Asthma (poorly controlled or steroid dependent)
➤	Bariatric surgery
➤	Cholestasis of pregnancy (abnormal bile acids $> 10\mu\text{mol/L}$)
➤	Chronic liver disease
➤	Chronic medical condition that may affect fetal growth due to utero-placental insufficiency
➤	Connective tissue disorders (lupus, RA, scleroderma, Sjogren's)
➤	Cystic Fibrosis/Known carrier of Spinal Muscular Atrophy (SMA), CF, Tay-Sachs genetic diseases
➤	Heart disease (Maternal) – New York Heart Association class III or IV greater or arrhythmia
➤	Hemoglobinopathies (e.g. sickle cell disease, sickle cell trait, thalassemia etc)
➤	History of endometrial ablation or Uterine Artery embolization

➤ Hyperthyroidism
➤ Hypothyroidism (poorly controlled)
➤ Maternal malnutrition (BMI < 18.5), for poor weight gain, send to MD Review
➤ Maternal blood clotting disorder/thrombophilia (Antiphospholipid Syndrome, Factor V Leiden mutation, Antithrombin III deficiency, Protein C/Protein S deficiency, etc.)
➤ PKU
➤ Renal disease such as pyelonephritis, glomerulonephritis, or persistent protein in the urine renal insufficiency
➤ Seizure disorders
➤ Systemic malignancy
➤ Fetal Ventriculomegaly

OB-11.1.d: Previous pregnancy related risk factors

➤ If no known cause of miscarriages < 20 weeks:
◆ 2 or more miscarriages and currently ≥ 35 years old; or
◆ 3 or more miscarriages and currently < 35 years old
➤ Prior pregnancy with placental abnormality (Infarcts, Accreta)
➤ Prior pregnancy with SGA (baby weighing < 2500 grams at term or FGR less than the 10 th percentile of expected weight)
➤ Prior pregnancy with adverse outcome (early onset preeclampsia ≤ 34 weeks, abruption, or FGR at any gestational age, nonimmune hydrops)
➤ Rh sensitization/Isoimmunization in prior pregnancy. In current pregnancy see: OB-3: Alloimmunization/Rh Isoimmunization/Other Causes of Fetal Anemia/Parvo/Hydrops

OB-11.1.e: Current pregnancy related risk factors

➤ Abnormal MSAFP/Low PAPP_A/Known chromosomal abnormalities/abnormal FNT, or abnormal cfDNA
➤ Any 'significant' congenital anomaly or fetal congenital heart disease
➤ Gastroschisis in current pregnancy
➤ ART Conception with assisted reproductive technologies/ART
➤ Grand multiparity: must have completed 5 or more pregnancies of greater than 20 weeks gestation, living or stillbirth (does not include current pregnancy; twins count as 1 pregnancy)
➤ Thickened nuchal fold ≥ 5 mm at 16 to 20 weeks; ≥ 6mm at 20 to 22 weeks (if CPT® 76811 shows adequate heart views, then no indication for echo)
➤ No prenatal care prior to 28 weeks

OB-11.1.f: Maternal Infections

➤ Acquired Immune Deficiency Syndrome/HIV Positive
➤ Cytomegalovirus (CMV)
➤ Malaria
➤ Known parvovirus in current pregnancy post fetal treatment. See: OB-3.2: Exposure to Parvovirus B-19
➤ Rubella
➤ Syphilis, untreated
➤ Toxoplasmosis
➤ Tuberculosis

OB-11.1.g: Imaging For Above Conditions

- Perform one ultrasound in the first trimester to establish dates, and report one of the following:
 - ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, **and/or**
 - ◆ CPT® 76817 for a transvaginal ultrasound indicated.
- Detailed Fetal Anatomic Scan CPT® 76811 ideally performed between 18 to 20 weeks, but be performed after 16 weeks when criteria is met:
 - ◆ Performance of the specialized fetal anatomic evaluation should be limited to those with special skills to perform this study, such as Maternal-Fetal Medicine specialists, Perinatologists, and Radiologists (**with advanced training in fetal imaging**)
 - ◆ There is no prior approval for a CPT® 76811 for the current pregnancy
- Starting at 23 to 24 weeks, follow-up growth scans (CPT® 76816) every 3 to 6 weeks
- Starting at 32 weeks, weekly BPP (CPT® 76818 or CPT® 76819) or AFI (CPT® 76815) with NST

OB-11.2: High Risk Group Two – Findings on Ultrasound That May Require Further Imaging**OB-11.2.a: High Risk Group Two a.**

- If the following conditions are found upon routine imaging:
 - ◆ Shortened femur identified in fetus of current pregnancy
 - ◆ Shortened humerus identified in fetus of current pregnancy
 - ◆ Pyelectasis of > 4 mm at 20 weeks identified in fetus of current pregnancy
 - ◆ Echogenic bowel identified in fetus of current pregnancy
 - ◆ Hypoplastic nasal bone in current pregnancy
- Fetal anatomic scan is ideally performed at 18 to 20 weeks but must be performed after 16 weeks (CPT® 76811)
- One follow-up scan (CPT® 76816) in third trimester

OB-11.2.b: High Risk Group Two b.

- If the following conditions are found upon routine imaging:
 - ◆ Choroid plexus cyst (present in 30% to 50% of all Trisomy 18 fetuses). Follow-up imaging not needed if targeted scan is normal
 - ◆ Echogenic intracardiac foci (present in 15% to 30% of all Down syndrome fetuses). Fetal echo or follow-up ultrasound are not warranted
 - ◆ Prior pregnancy with a congenital anomaly
 - ◆ Chromosomal abnormalities with previous pregnancy
- Fetal anatomic scan is ideally performed at 18 to 20 weeks but must be performed after 16 weeks (CPT® 76811)

OB-11.3: High Risk Group Three – BMI

OB-11.3.a: Pre-pregnancy BMI 30 to 34

Obesity (BMI 30-34)	
➤	Perform one ultrasound in the first trimester to establish dates and report one of the following: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, and/or ◆ CPT® 76817 for a transvaginal ultrasound indicated
➤	Fetal anatomic scan is ideally performed at 18 to 20 weeks but must be performed after 16 weeks (CPT® 76811)
➤	One follow-up scan (CPT® 76816) between 32 to 36 weeks

OB-11.3.b: Pre-pregnancy BMI 35-39

Obesity (BMI 35-39)	
➤	Perform one ultrasound in the first trimester to establish dates, and report one of the following: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, and/or ◆ CPT® 76817 for a transvaginal ultrasound indicated
➤	Fetal anatomic scan is ideally performed at 18 to 20 weeks but must be performed after 16 weeks (CPT® 76811)
➤	Growth scan (CPT® 76816) at 32 and 36 weeks, and CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST weekly starting at 36 weeks

OB-11.3.c: Pre-pregnancy BMI ≥ 40

Obesity (BMI ≥ 40)	
➤	Perform one ultrasound in the first trimester to establish dates, and report one of the following: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, and/or ◆ CPT® 76817 for a transvaginal ultrasound indicated
➤	Fetal anatomic scan is ideally performed at 18 to 20 weeks but must be performed after 16 weeks (CPT® 76811)
➤	Growth scan (CPT® 76816) at 32 and 36 weeks
➤	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST weekly starting at 32 weeks
➤	If A1C is greater than 6.5: fetal echo CPT® 76825 and/or CPT® 76827 and/or CPT® 93325 after 18 weeks

Practice Note

The obesity protocol that was introduced in 2011 included recommendations for early gestational diabetes mellitus screening and an overall pregnancy weight gain of 11 to 20 pounds in all classes of obesity. A baseline 24-hour urine protein collection was recommended for class II and class III obese patients based on their increased risk of developing gestational diabetes mellitus and preeclampsia^{6,7,8,9} in addition to serial growth scans and nonstress tests also being utilized. Delivery by the estimated due date was recommended for each class of obesity meeting the following criteria: (1) class III obese (pre-pregnancy body mass index of 40 kg/m² or greater) alone, (2) class II obese (pre-pregnancy body mass index of 35 to 39.9 kg/m²) and a diagnosis of gestational diabetes mellitus or large for gestational age, or (3) class I obese (pre-pregnancy body mass index of 30 to 34.9 kg/m²) plus a diagnosis of gestational diabetes mellitus and large for gestational age/fetus. Large for gestational age/macrosomia was defined as an estimated fetal weight of greater than the 95th percentile.

OB-11.4: High Risk Group Four**OB-11.4.a: Prior Pregnancy with Macrosomia****Prior pregnancy with macrosomia (baby weighing > 4000 grams at term or greater than the 90th percentile of expected weight)**

- Perform one ultrasound in the first trimester to establish dates, and report one of the following:
 - ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, **or** CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound, indicated if less than 14 weeks.
- One targeted scan (CPT® 76811) in second-trimester ≥ 16 weeks
- One growth scan (CPT® 76816) at > 30 weeks

OB-11.4.b: Current Pregnancy with Suspected or Known Macrosomia

- See: **OB-8.2: Macrosomia-Large for Dates Current Pregnancy** and **OB-22: Unequal Fundal Size and Dates**

OB-11.5: High Risk Group Five: Zika Virus

➤ Suspected exposure without symptoms: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, or CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks ◆ Anatomy scan CPT® 76805 (plus CPT® 76810 if more than one fetus) if a complete ultrasound has not yet been performed during this pregnancy ◆ Starting at 16 weeks, Growth scan (CPT® 76816) every 3 to 4 weeks to monitor for findings such as intracranial calcifications and microcephaly
➤ Suspected exposure with symptoms or known disease: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, or CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound, indicated if less than 14 weeks; ◆ Detailed fetal anatomic scan (CPT® 76811) may be performed at 16 weeks gestation or greater. ◆ Growth scan, (CPT® 76816) every 3 to 4 weeks to monitor for findings such as intracranial calcifications and microcephaly, starting at 16 weeks. ◆ If diagnosed FGR or abdominal circumference ≤ 10 percentile then follow FGR imaging OB-8.1: Fetal Growth Restriction Current Pregnancy
➤ If intracranial calcifications, microcephaly or other abnormalities emerge, send to MD review. In these cases, imaging would follow the algorithm of other viruses that cause congenital infection OB 11.1.f: Maternal Infections.

OB-11.6: High Risk Group 6 – Pre-Gestational Diabetes on Oral Medications or Insulin

If patient has pre-gestational diabetes and is on oral medication or insulin:			
Test	When	Frequency	Codes
First Trimester Ultrasounds	< 14 weeks	Once	CPT® 76801 and/or CPT® 76817
Fetal anatomic scan	16 to 20 weeks	Once	CPT® 76811
Fetal echo (initial) Requests for follow-up go to MD review	Starting at 18 to 24 weeks	Once	CPT® 76825 and/or CPT® 76827 and/or CPT® 93325
Ultrasound (for fetal growth)	Starting at viability 23 to 24 weeks	Every 2 to 4 weeks	CPT® 76816*
Biophysical Profile (BPP) or AFI with NST*	If complicated by additional risk factors, perform between 26 and 28 weeks	Up to twice weekly	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST*
Biophysical Profile* (BPP) or AFI with NST**	Starting at 32 weeks	Up to twice weekly	CPT® 76818 or CPT® 76819 (BPP) or CPT® 76815 for AFI with NST*
Umbilical artery Doppler (if FGR diagnosed)	Upon diagnosis of FGR	Weekly	CPT® 76820

For a poorly controlled diabetic, requests for a repeat fetal echocardiogram will be sent to MD review. (HbA1C > 6.5 is associated with fetal anomalies and adverse outcomes. Reference Table 1 below)

*Starting at 32 weeks, AFI CPT® 76815 can be substituted for BPP but not for the same day of service.

**NST is not currently prior authorized by eviCore healthcare for any health plan.

***If there has not been a prior anatomical scan, this can be done at greater than 20 weeks.

Practice Note

Table 1

Serious adverse outcomes (congenital malformations and/or perinatal mortality) in offspring of women with type 1 diabetes and background population according to periconceptional glycemic control

A1C (%)	z score (SD > mean)	Number of patients	Congenital malformations (%)	RR (95% CI) vs. background population	Perinatal mortality (%)	RR (95% CI) vs. background population	Serious adverse outcome (%)	RR (95% CI) vs. background population
≥ 10.4	≥10	55	10.9	3.9 (1.8 to 7.8) [‡]	5.5	7.3 (2.5 to 19.8) [‡]	16.3	4.7 (2.5 to 8.1) [‡]
8.9 to 10.3	7.0 to 9.9	128	3.9	1.4 (0.6 to 3.1)	6.3	8.3 (4.2 to 15.9) [‡]	7.8	2.2 (1.2 to 3.9) [‡]
7.9 to 8.8	5.0 to 6.9	182	5.0	1.8 (0.9 to 3.3)	3.3	4.4 (2.0 to 9.4) [‡]	7.7	2.2 (1.3 to 3.6) [‡]
6.9 to 7.8	3.0 to 4.9	284	4.9	1.8 (1.0 to 2.9)	2.8	3.8 (1.9 to 7.3) [‡]	7.7	2.2 (1.5 to 3.3) [‡]
< 6.9	< 3.0	284	3.9	1.4 (0.8 to 2.4)	2.1	2.8 (1.3 to 6.1) [‡]	5.6	1.6 (1.0 to 2.6)
Background population (n = 70,089)			2.8	1.0	0.75	1.0	3.5	1.0

*Standard reference 5.4 ± 1.0 (mean ± 2 SD) in the nondiabetic background population.

*Significantly higher than background population at significance level of 0.05 relative risk (Jensen DM et al, 2017)

OB-11.7: High Risk Group Seven Gestational Diabetes

OB-11.7.a: Gestational Diet-Controlled

If patient has gestational diabetes and it is diet controlled:			
Test	When	Frequency	Codes
Fetal anatomic scan	16 to 20 weeks***	Once	CPT® 76805
Ultrasound (for fetal growth)	Starting at 32 weeks	Every 4 weeks	CPT® 76816*
Biophysical Profile* (BPP) or AFI with NST**	Starting at 34 to 36 weeks	Once weekly if diet controlled.	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST**
Maternal diet-controlled diabetes refers to patients that have a diagnosis of any type of diabetes (including diet-controlled gestational diabetes mellitus (GDM) and diet controlled pre-gestational diabetes mellitus) but require no medication for their diabetes. If HbA1C is > 6.5%, then they are not controlled and should follow guidelines for medication utilized for control see also <u>OB-11.6: High Risk Group 6- Pre-Gestational Diabetes On oral medications or insulin</u> *Starting at 35 weeks, AFI CPT® 76815 can be substituted for BPP but not for the same day of service. **NST is not currently prior authorized by eviCore healthcare for any health plan. ***If there has not been a prior anatomical scan, this can be done at greater than 20 weeks.			

OB-11.7.b: Gestational Diabetes on Oral Medications or Insulin

If patient has gestational diabetes and is on oral medication or insulin:			
Test	When	Frequency	Codes
Fetal anatomic scan	16 to 20 weeks***	Once	CPT® 76811
Fetal echo (initial) Requests for follow-up go to MD review	Starting at 18 to 24 weeks	Once	CPT® 76825 and/or CPT® 76827 and/or CPT® 93325
Ultrasound (for fetal growth)	Starting at viability 23 to 24 weeks	Every 2 to 4 weeks	CPT® 76816*
Biophysical Profile (BPP) or AFI with NST*	If complicated by additional risk factors perform between 26 and 28 weeks	Up to twice weekly	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST**
Biophysical Profile* (BPP) or AFI with NST**	Starting at 32 weeks	Up to twice weekly	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI with NST**
Umbilical artery Doppler (if FGR diagnosed)	Upon diagnosis of FGR	Weekly	CPT® 76820
For a poorly controlled diabetic, requests for a repeat fetal echocardiogram will be sent to MD review. (If HbA1C is > 6.5%, fetal echo can be performed in the third trimester to assess for ventricular hypertrophy)			
*Starting at 32 weeks, AFI CPT® 76815 can be substituted for BPP but not for the same day of service. **NST is not currently prior authorized by eviCore healthcare for any health plan. ***If there has not been a prior anatomical scan, this can be done at greater than 20 weeks.			

OB-11.8: Hypertension

Current chronic hypertension, on and not on prescribed medications, and/or History of preeclampsia, and/or History of FGR:	
➤ One time uterine artery Doppler (CPT® 93976) evaluation prior to < 16 weeks gestation. Uterine artery Doppler is not indicated > 16 weeks. ➤ If test is abnormal at less than 16 weeks, a repeat test can be considered at 20 to 22 weeks gestation after starting baby aspirin. (CPT® 93976) (See: OB-24.10: Duplex Scan (Uterine Artery))	
If patient has one of the following hypertension-related conditions:	
Chronic hypertension not on prescribed hypertension medication:	
➤ Perform one ultrasound in the first trimester to establish dates, and report one of the following: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, or CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks. ◆ One US at 16 to 20 weeks (CPT® 76811- Detailed fetal anatomic section); and one US (CPT® 76816) at 30 to 34 weeks only. (If blood pressure is elevated from baseline, see Gestational Hypertension(GH) below)	
Chronic hypertension on prescribed hypertension medication:	
➤ Perform one ultrasound in the first trimester to establish dates, and report one of the following: ◆ CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, or CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks.	
➤ One Detailed Fetal Anatomic Scan at 16 weeks gestation or greater	CPT® 76811
➤ US every 3 to 4 weeks starting at viability 23 to 24 weeks gestation	CPT® 76816
➤ Starting at 32 weeks, weekly biophysical profile (BPP) or AFI with NST*	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI
➤ If other risk factors are present, may start at 26 to 28 weeks.	
➤ If diagnosed FGR, weekly umbilical artery Doppler (See: OB-8.1: Fetal Growth Restriction Current Pregnancy)	CPT® 76820
Gestational Hypertension (GH, preeclampsia, toxemia):	
➤ Starting at time of diagnosis, growth US every 3 to 4 weeks	CPT® 76816
➤ If FGR, Oligohydramnios, or Severe preeclampsia, growth US every 2 to 4 weeks.	
➤ Starting at time of diagnosis, weekly BPP or AFI with NST*	CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI
➤ If FGR or Oligohydramnios is also present, twice weekly BPP or AFI with NST*	
➤ Only if FGR or Oligohydramnios is present, twice weekly umbilical artery Doppler	CPT® 76820
➤ MCA Doppler (CPT® 76821), starting at 34 weeks. Once weekly only following a normal 76820 Doppler	
*NST (CPT® 59025) is not currently prior authorized by eviCore health care for any health plan	

OB-11.9: Single Umbilical Artery

If single umbilical artery is found on initial imaging:	
➤ Detailed anatomic ultrasound at 16 weeks or greater	CPT® 76811
➤ Fetal echocardiogram at 23 to 24 weeks	CPT® 76825 and/or CPT® 76827 and/or CPT® 93325
➤ Follow-up ultrasound to evaluate fetal growth at 28 to 32 weeks and then every 3 to 6 weeks if more than one clinical high-risk factors are documented	CPT® 76816
➤ Weekly BPP or AFI with NST starting at 36 weeks	CPT® 76818 or CPT® 76819 (BPP) or CPT® 76815 (AFI) with NST

OB-11.10: History of Pre-Term Delivery/History of PPROM

OB-11.10.a: Preterm Delivery ≤ 34 Weeks; History of PPROM ≤ 34 weeks

- Ultrasound CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed once in first trimester **and/or** CPT® 76817 for transvaginal ultrasound once in first trimester (less than 14 weeks) to establish dates
- Ultrasound is supported at 16 weeks or greater: CPT® 76811 [plus CPT® 76812 if more than one fetus] **and/or** CPT® 76817 if a complete detailed fetal anatomic scan has not yet been performed during this pregnancy for any one of the above conditions
 - ◆ Starting after the fetal anatomic scan at 23 weeks or greater, ultrasound (CPT® 76816) can be performed every 3 to 6 weeks until delivery
 - ◆ (CPT® 76815 and/or CPT® 76817) every 2 weeks, starting at 16 weeks or greater until 24 weeks
 - ◆ Starting at 32 weeks, weekly BPP CPT® 76818 or CPT® 76819 or CPT® 76815 for AFI

OB-11.10.b: History of Preterm Delivery > 34 weeks < 37

- CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed **and/or** CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks to establish dates
- (CPT® 76815 and/or CPT® 76817) every 2 weeks, starting at 16 weeks or greater until 24 weeks
- An anatomy ultrasound is supported at 16 weeks or greater: CPT® 76805 [plus CPT® 76810 if more than one fetus] **and/or** CPT® 76817 if a complete fetal anatomic scan has not yet been performed during this pregnancy.

OB-11.11: History of Stillbirth

Women with a history of stillbirth:

- CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, **or** CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, **and/or** CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks
- Fetal anatomic scan at 16 weeks or greater (CPT® 76811)
- Ultrasound (CPT® 76816) every 2 to 4 weeks to assess fetal growth starting at 23 to 24 weeks or two weeks before prior pregnancy loss.
- Weekly BPP (CPT® 76818 or CPT® 76819) **or** CPT® 76815 for AFI with NST starting at 32 weeks or two weeks before prior pregnancy loss

References

1. Practice Bulletin No. 175: Summary. Ultrasound in pregnancy. Obstet Gynecol. 2016; 128(6):1459-1460. Accessed November 3, 2017.
http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.
2. Practice Bulletin No. 132: Antiphospholipid Syndrome. Obstetrics & Gynecology. 2012; 120:1514–21, reaffirmed in 2017. Accessed November 15, 2017,
http://journals.lww.com/greenjournal/Abstract/2012/12000/Practice_Bulletin_No_132_Antiphospholipid.44.aspx.
3. Practice Bulletin No. 145: Antepartum Fetal Surveillance. Obstetrics & Gynecology. 2014;124(1):182-192, reaffirmed in 2016. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2014/07000/Practice_Bulletin_No_145_Antepartum_Fetal.35.aspx.
4. Practice Bulletin No. 78: Hemoglobinopathies in Pregnancy. Obstetrics & Gynecology. 2007, reaffirmed 2015; 109(1):229-238. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2007/01000/ACOG_Practice_Bulletin_No_78_Hemoglobinopathies.55.aspx.
5. Dawood F. Inherited and Acquired Thrombophilia in Pregnancy. Thrombophilia. September 2011. Accessed November 15, 2017. <https://www.intechopen.com/books/thrombophilia/inherited-and-acquired-thrombophilia-in-pregnancy>.
6. Copel JA, Bahtiyar MO. A practical approach to fetal growth restriction. Obstetrics & Gynecology, 2014; ;123(5):1057-1069. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Abstract/2014/05000/A_Practical_Approach_to_Fetal_Growth_Restriction.22.aspx.
7. ACOG Practice Bulletin No. 102: Management of Stillbirth. Obstetrics & Gynecology. 2009, reaffirmed 2016; 113(3):748-761. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2009/03000/ACOG_Practice_Bulletin_No_102_Management_of.32.aspx.
8. Towers CV, Carr MH. Antenatal fetal surveillance in pregnancies complicated by fetal gastroschisis. Am J Obstet Gynecol 2008;198(6):686. Accessed November 15, 2017.
[http://www.ajog.org/article/S0002-9378\(08\)00288-3/pdf](http://www.ajog.org/article/S0002-9378(08)00288-3/pdf).
9. Silver RM, Varner MW, Reddy U et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol, 2007; 196(5):433-444. Accessed November 15, 2017.
<https://www.medscape.com/medline/abstract/17466694>.
10. Garodosi J, Madurasinghe V, Williams M et al. Maternal and fetal risk factors for stillbirth: population based study. BMJ, 2013;346. Accessed November 15, 2017.
<http://www.bmj.com/content/346/bmj.f108>.

11. Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society of Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. *Obstet Gynecol Survey*. 2014;69(8):453-455. Accessed November 15, 2017. http://journals.lww.com/obgynsurvey/Abstract/2014/08000/Fetal_Imaging_Executive_Summary_of_a_Joint.4.aspx.
12. Donofrio MT, Moon-Grady AJ, Hornberger LK et al. Diagnosis and treatment of fetal cardiac disease: A scientific statement from the American Heart Association. *Circulation*, 2014; 129(21):2183-242. Accessed November 15, 2017. <https://www.medscape.com/medline/abstract/24763516>.
13. Baschat AA, Cosmi E, Bilardo CM et al. Predictors of neonatal outcome in early-onset placental dysfunction. *Obstet Gynecol*, 2007;109:253–61. Accessed November 15, 2017. <http://journals.lww.com/greenjournal/Pages/articleviewer.aspx?year=2007&issue=02000&article=00004&type=Fulltext>.
14. Oros D, Figueras F, Cruz–Martinez R et al. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late–onset small–for–gestational age fetuses. *Ultrasound Obstet Gynecol*, 2011;37:191–5. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7738/pdf>
15. Reddy UM, Filly RA, Copel JA. Prenatal Imaging: Ultrasonography and Magnetic Resonance Imaging. *Obstetrics and Gynecology*, 2008;112(1):145-157. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7738/pdf>.
16. Sciscione AC, Hayes EJ. Uterine artery Doppler flow studies in obstetric practice. *American J Obstet Gynecol*, 2009; 201(2):121-126. Accessed November 15, 2017. [http://www.ajog.org/article/S0002-9378\(09\)00283-X/fulltext](http://www.ajog.org/article/S0002-9378(09)00283-X/fulltext).
17. Practice Bulletin No. 134. Fetal Growth Restriction. *Obstetrics & Gynecology*. 2013, reaffirmed 2015; 121(5):1122-1133 Accessed November 15, 2017. http://journals.lww.com/greenjournal/Abstract/2013/05000/Practice_Bulletin_No_134_Fetal_Growth_Restriction.45.aspx.
18. Copel JA, Bahtiyar MO. A practical approach to fetal growth restriction. *Obstetrics & Gynecology*, 2014;123(5):1057-1069. Accessed November 16, 2017. http://journals.lww.com/greenjournal/Abstract/2014/05000/A_Practical_Approach_to_Fetal_Growth_Restriction.22.aspx.
19. Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55 974 women. *Ultrasound in Obstetrics & Gynecology*. 2014;43(5):500-507. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.13275/epdf>.
20. ACOG Practice Advisory: Interim Guidance for Care of Obstetric Patients During a Zika Virus Outbreak. February 2016, reaffirmed: September 13, 2017. Accessed November 16, 2017. <https://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Interim-Guidance-for-Care-of-Obstetric-Patients-During-a-Zika-Virus-Outbreak>
21. Schuster M, Madueke-Laveaux OS, Mackeen AD, et al. The effect of the MFM obesity protocol on cesarean delivery rates. *Am J Obstet Gynecol*. 2016;215:492.e1-6. Accessed November 16, 2017. <https://www.deepdyve.com/lp/elsevier/the-effect-of-the-mfm-obesity-protocol-on-cesarean-delivery-rates-8qCwH0fw6g>.
22. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care*, 2009;32(6):1046-1048. Accessed November 16, 2017. <http://care.diabetesjournals.org/content/diacare/32/6/1046.full.pdf>.
23. Practice Bulletin No.180: Gestational Diabetes Mellitus. *Obstetrics & Gynecology*. 2017; 130(1)e17-e37. Accessed November 16, 2017. http://journals.lww.com/greenjournal/Abstract/2017/07000/Practice_Bulletin_No_180_Gestational_Diabetes.51.aspx.
24. Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, et al. Maternal age and risk of labor and delivery complications. *Maternal and child health journal*. 2015;19(6):1202-1211. Accessed November 16, 2017. <https://link.springer.com/article/10.1007/s10995-014-1624-7>.

25. McCarthy FP, O'Brien U, Kenny LC. The management of teenage pregnancy. *BMJ*. 2014;349:g5887. Accessed November 16, 2017. <http://www.bmj.com/content/349/bmj.g5887>.
26. Machado JB, Filho PV, Petersen GO et al. Quantitative effects of tobacco smoking exposure on the maternal-fetal circulation. *BMJ* 2011 11:24. Accessed November 16, 2017. <https://bmcpregnancychildbirth.biomedcentral.com/track/pdf/10.1186/1471-2393-11-24?site=bmcpregnancychildbirth.biomedcentral.com>.
27. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. *Human Reproduction Update*. 2011;17(5):589-604. Accessed November 16, 2017. <https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmr022>.
28. Adams J. Statement of the Public Affairs Committee of the Teratology Society on the Importance of Smoking cessation in pregnancy. 2003;67(11):895-899. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/bdra.10140/abstract>
29. Practice Bulletin No.150: Early Pregnancy Loss. *Obstetrics & Gynecology* 2015; 125(5):1258-1267, reaffirmed 2017. Accessed November 16, 2017. <https://www.acog.org/-/media/Practice-Bulletins/Committee-on-Practice-Bulletins----Gynecology/Public/pb150.pdf?dmc=1&ts=20171116T1423413474>.
30. Warner TD, Roussos-Ross D, Behnke M. It's Not Your Mother's Marijuana: Effects on Maternal-Fetal Health and the Developing Child. *Clinics in perinatology*. 2014;41(4):877-894. Accessed November 16, 2017. <http://www.manuellosses.cl/pneo/5.%20Efectos%20de%20la%20marihuana%20madre%20feto%20rn.pdf>.
31. Lengyel CS, Ehrlich S, Iams JD et al. It's not your mother's marijuana. Effect of modifiable risk factors on preterm birth. *Maternal Child Health Journal*. (2017)21:777–785. Accessed November 16, 2017. <http://www.manuellosses.cl/pneo/5.%20Efectos%20de%20la%20marihuana%20madre%20feto%20rn.pdf>.
32. Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. 2017; 130(3):e205-e209. Accessed November 16, 2017. <https://www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/co722.pdf?dmc=1&ts=20171116T1445207875>.
33. Pfeifer S, Fritz M, Goldberg J et al. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertility and Sterility*. 2012; 98(5):1103-11. Accessed November 16, 2017. http://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/for-non-members/evaluation_and_treatment_of_recurrent_pregnancy_loss_a_committee_opinion-noprint.pdf.
34. Jevé YB, Davies W. Evidence-based management of recurrent miscarriages. *Journal of Human Reproductive Sciences*. 2014;7(3):159-169. Accessed November 16, 2017. <http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2014;volume=7;issue=3;spage=159;epage=169;aulast=Jevé>.
35. McIntosh J, Feltovich H, Berghella V et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. *SMFM Consult #40*. 2016;215(3):B2-B7. Accessed November 16, 2017. <https://www.scribd.com/document/330602388/MMF-Cervical-Length-16>.
36. Practice Bulletin No. 90: Asthma in Pregnancy. *Obstetrics & Gynecology*. 2008; 111(2):457-464, reaffirmed 2016. Accessed November 16, 2017. http://journals.lww.com/greenjournal/Citation/2008/02000/ACOG_Practice_Bulletin_No_90_Asthma_in.34.aspx.
37. Practice Bulletin No. 60: Pregestational Diabetes Mellitus. *Obstetrics & Gynecology*. 2005; 105(3):675-685, reaffirmed 2016. Accessed November 16, 2017. http://journals.lww.com/greenjournal/Citation/2005/03000/ACOG_Practice_Bulletin_60_Pregestatio_nal.49.aspx.
38. Practice Bulletin No. 156: Obesity in Pregnancy. *Obstetrics & Gynecology* 2016; 126:e112–26). Replaces Committee Opinion Number 549, January 2013 Accessed November 16, 2017. http://journals.lww.com/greenjournal/Fulltext/2016/12000/Practice_Bulletin_No_156_Obesity_in_Pregnancy_.45.aspx.

39. Practice Bulletin No. 171: Management of Preterm Labor. Obstetrics & Gynecology. October 2016 ; 128(4):e155–64. Replaces Practice Bulletin Number 159, January 2016 (Interim Update) Accessed November 16, 2017. <https://www.medscape.com/medline/abstract/27661654>.
40. Wax J, Minkoff H, Johnson A et al. Consensus report on detailed fetal anatomic ultrasound examination. Journal ultrasound medicine. 2014;33(2):189-195. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.7863/ultra.33.2.189/abstract>.
41. Voskamp BJ, Fleurke-Rozema H, Oude-Rengerink K, et al. Relationship of isolated single umbilical artery to fetal growth, aneuploidy and perinatal mortality: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology. 2013;42(6):622-628. <https://doi.org/10.1002/uog.12541>
42. Caldas LM, Liao A, Carvalho MH, et al. Should fetal growth be a matter of concern in isolated single umbilical artery? Revista da Associação Médica Brasileira. 2014;60(2):125-130. <http://dx.doi.org/10.1590/1806-9282.60.02.009>.
43. Battarbee AN, Palatnik A, Ernst LM, et al. Association of Isolated Single Umbilical Artery With Small for Gestational Age and Preterm Birth. Obstetrics & Gynecology. 2015;126(4):760-764. https://journals.lww.com/greenjournal/fulltext/2015/10000/Association_of_Isolated_Single_Umbilical_Artery.11.aspx. Accessed August 14, 2018.
44. Murphy-Kaulbeck L, Dodds L, Joseph K, Hof MVD. Single Umbilical Artery Risk Factors and Pregnancy Outcomes. Obstetrics & Gynecology. 2010;116(4):843-850. https://journals.lww.com/greenjournal/fulltext/2010/10000/Single_Umbilical_Artery_Risk_Factors_and_Pregnancy.9.aspx. Accessed August 14, 2018.
45. Hua M, Odibo AO, Macones GA, Roehl KA, Crane JP, Cahill AG. Single Umbilical Artery and Its Associated Findings. Obstetrics & Gynecology. 2010;115(5):930-934. https://journals.lww.com/greenjournal/fulltext/2010/05000/Single_Umbilical_Artery_and_Its_Associate.d.10.aspx. Accessed August 14, 2018.
46. Egan N, Bartels Ä, Khashan A, et al. Reference standard for serum bile acids in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 2012;119(4):493-498. <https://doi.org/10.1111/j.1471-0528.2011.03245.x>.

OB-12: History of Infertility

OB-12.1: History of Infertility	60
OB-12.2: Present Pregnancy with Use of Fertility Drugs and Treatment (ART)	60

OB-12.1: History of Infertility

- Ultrasound imaging is supported if there is a history of infertility treatment (CPT® 76801 [plus CPT® 76802 if more than one fetus] and/or CPT® 76817 for transvaginal ultrasound)
- Repeat ultrasound is not usually necessary unless there are new clinical indications

OB-12.2: Present Pregnancy with use of Fertility Drugs and Treatment (ART)

- Follow high risk imaging, see **OB-11: High Risk Pregnancy**

OB-13: Cervical Insufficiency/Current Preterm Labor

OB-13.1: Cervical Insufficiency	62
OB-13.2: Cerclage in place in current pregnancy	62
OB-13.3: Current Preterm Labor	62

For history of pre-term labor see: **OB-11.10: History of Pre-Term Delivery/History of PPRM**

OB-13.1: Cervical Insufficiency

- For any of the following:
 - ◆ History of prior precipitous delivery
 - ◆ Presence of uterine anomaly (See: **OB-23.3: Uterine Anomalies**)
 - ◆ History of cerclage in prior pregnancy
 - ◆ Over dilation of cervix during a termination of pregnancy
 - ◆ Cervical obstetrical laceration from a previous delivery
 - ◆ Surgical trauma to cervix (e.g. conization [CKC—cold-knife conization] or Loop Electrosurgical Excision Procedure [LEEP])
- Perform one ultrasound in the first trimester to establish dates, and report one of the following; CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, and/or CPT® 76817 for a transvaginal ultrasound indicated
- Ultrasound is supported at 16 weeks or greater: CPT® 76805 [plus CPT® 76810 if more than one fetus] **and/or** CPT® 76817 once if a complete fetal anatomic scan has not yet been performed during this pregnancy.
- Starting after the fetal anatomic scan at 16 weeks or greater, ultrasound (CPT® 76815) every 2 to 4 weeks **and/or** transvaginal ultrasound (CPT® 76817) every 2 weeks until 24 weeks

If funneling or abnormally shorten cervix ≤ 25 mm (2.5 cm) is found on a transvaginal ultrasound in a singleton pregnancy, an ultrasound (CPT® 76816 or CPT 76815) every 2 to 4 weeks for the duration of the pregnancy **and/or** (CPT® 76817) for transvaginal ultrasound every 1 to 2 weeks until 32 weeks.

OB-13.2: Cerclage in place in current pregnancy

- Ultrasound CPT® 76801[plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed once in first trimester, or CPT® 76815 for limited ultrasound if a complete ultrasound 76801 has already been performed and/or CPT® 76817 for transvaginal ultrasound once in first trimester (less than 14 weeks) for any one of the following:
 - ◆ Ultrasound is supported at 16 weeks or greater: CPT® 76811 [plus CPT® 76812 if more than one fetus] and/or CPT® 76817 once, if a complete detailed fetal anatomic scan has not been done.
 - ◆ Starting after the fetal anatomic scan at 16 weeks or greater, ultrasound (CPT® 76815 or CPT® 76816) can be performed every 3 to 6 weeks.
 - ◆ Transvaginal (CPT® 76817) every 2 weeks, starting at 16 weeks or greater until 30 weeks if a rescue cerclage was placed.

OB-13.3: Current Preterm Labor

- Known preterm labor in current pregnancy (contractions with cervical change) CPT® 76805 [plus CPT® 76810 if more than one fetus] **and/or** CPT® 76817 if a complete fetal anatomic scan has not yet been performed during this pregnancy; if a complete fetal anatomic scan was performed previously, CPT® 76815 **or** CPT® 76816 (76816 no more than every 2 weeks) when symptomatic

- CPT® 76817 once or when symptomatic
- Once or when symptomatic, biophysical profile (BPP) (CPT® 76818 or CPT® 76819) or AFI CPT® 76815 with NST, starting at 30 weeks; if less than 30 weeks send to MD review

References

1. Miller ES, Tita AT, Grobman WA. Second-Trimester Cervical Length Screening Among Asymptomatic Women. *Obstetrics & Gynecology*. 2015;126(1):61-66.
[https://journals.lww.com/greenjournal/fulltext/2015/07000/Second Trimester Cervical Length Screening_Among.10.aspx](https://journals.lww.com/greenjournal/fulltext/2015/07000/Second_Trimester_Cervical_Length_Screening_Among.10.aspx). Accessed August 14, 2018.
2. Practice Bulletin No. 142. *Obstetrics & Gynecology*. 2014;123(2, PART 1):372-379 Reaffirmed 2016.
[doi:10.1097/01.aog.0000443276.68274.cc](https://doi.org/10.1097/01.aog.0000443276.68274.cc).
3. Orzechowski KM, Boelig RC, Baxter JK, et al. A Universal Transvaginal Cervical Length Screening Program for Preterm Birth Prevention. *Obstetrics & Gynecology*. 2014;124(3):520-525.
[https://journals.lww.com/greenjournal/fulltext/2014/09000/A Universal Transvaginal Cervical Length Screening.7.aspx](https://journals.lww.com/greenjournal/fulltext/2014/09000/A_Universal_Transvaginal_Cervical_Length_Screening.7.aspx). Accessed August 14, 2018.
4. Practice Bulletin No. 130. Prediction and prevention of preterm birth. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2012;120:964–73. Reaffirmed 2018.
5. ACOG Practice Bulletin No. 171. Management of preterm labor. Practice Bulletin No. 171. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016;128:e155–64. Reaffirmed 2018.
6. Practice Bulletin No. 175: Summary: Ultrasound in pregnancy. *Obstetrics & Gynecology*. 2016;128(6):1459-1460. Accessed November 15, 2017.
[http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice Bulletin No 175 Summary Ultrasound in.50.aspx](http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx).
7. Society for Maternal-Fetal Medicine. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. *Am J Obstet Gynecol*. 2012;206(5):376-386. Accessed November 15, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/22542113>.
8. Cho, H.J. and Roh, H.J. Correlation Between Cervical Lengths Measured by Transabdominal and Transvaginal Sonography for Predicting Preterm Birth. *Journal of Ultrasound in Medicine*. 2016; 35:537–544. Accessed November 15, 2017.
<http://onlinelibrary.wiley.com/doi/10.7863/ultra.15.03026/epdf>.
9. McIntosh J, Feltovich H, Berghella V et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. *American Journal of Obstetrics and Gynecology*. 2016; 215(3):B2-B7. Accessed November 15, 2017. [http://www.ajog.org/article/S0002-9378\(16\)30112-0/fulltext](http://www.ajog.org/article/S0002-9378(16)30112-0/fulltext).
10. Khalifeh, Adeeb, Vincenzo Berghella, David Stamilio, and Laura Carlson Ultrasound approach for cervical length screening in preterm birth prevention. Dec 2016; 215(6) *American Journal of Obstetrics & Gynecology* 739-744.
11. Esplin MS, Elovitz MA, Iams JD, et al. Predictive accuracy of serial transvaginal cervical lengths and quantitative vaginal fetal fibronectin levels for spontaneous preterm birth among nulliparous women. *JAMA*. 2017;317(10):1047-1056. Accessed December 6, 2017.
<https://www.rtihs.org/sites/default/files/28462%20Hunter%202017%20Predictive%20accuracy%20of%20serial%20transvaginal%20cervical%20lengths%20and%20quantitative%20vaginal%20fetal%20fibronectin%20levels%20for%20spontaneous%20preterm%20birth%20among%20nulliparous%20women.pdf>.
12. Jain S, Kilgore M, Edwards, RK, et al. Revisiting the cost-effectiveness of universal cervical length screening: importance of progesterone efficacy. *A J Obstet Gynecol*. 2016 Jul;215(1):101.e1-101.e7. Accessed December 6, 2017. [http://www.ajog.org/article/S0002-9378\(16\)00215-5/fulltext](http://www.ajog.org/article/S0002-9378(16)00215-5/fulltext)

OB-14: Intrauterine Device (IUD)

OB-14.1: Locate an Intrauterine Device

65

OB-14.1: Locate an Intrauterine Device

- Ultrasound can be performed to locate an intrauterine device (IUD) (CPT® 76801 and/or CPT® 76817 if a complete ultrasound has not yet been performed)
 - ◆ CPT® 76815 for limited ultrasound, if complete ultrasound has already been performed, **and/or** CPT® 76817 for a transvaginal ultrasound

OB-15: Macrosomia

- See: OB-8.2: Macrosomia-Large for Dates Current Pregnancy
- See: OB-11.4: High Risk Group Four

OB-16: Multiple Pregnancies

OB-16.1: For Suspected multiple pregnancies	68
OB-16.2: For Known dichorionic multiple pregnancies	68
OB-16.3: For Known monochorionic-diamniotic or monochorionic-monoamniotic multiple pregnancies	69

OB-16.1: For Suspected multiple pregnancies:**For Suspected multiple pregnancies:**

- Ultrasound is appropriate to confirm **suspected** multiple pregnancy (CPT® 76801[plus CPT® 76802 if more than one fetus]) if less than 14 weeks.

OB-16.2: For Known dichorionic multiple pregnancies:**For Known dichorionic multiple pregnancies:**

- CPT® 76811[plus CPT® 76812 if more than one fetus] if greater than 14 weeks if a complete detailed anatomic scan CPT® 76811 has not yet been performed during this pregnancy
- Follow-up ultrasounds for all known dichorionic multiple pregnancies:
 - ◆ Ultrasound (CPT® 76816) every 4 to 6 weeks to assess fetal growth starting at 23 to 24 weeks gestation
 - ◆ Transvaginal ultrasound (CPT® 76817) is recommended only in twin gestations with significant cervical shortening ≤ 1.5 cm on a transabdominal evaluation ONLY if rescue cerclage is being considered. Send all these requests to MD Review
 - ◆ Weekly BPP (CPT® 76818 or CPT® 76819) **or** 76815 for AFI with NST, starting at 32 weeks or sooner if additional risk factors
 - ◆ Twice weekly BPP can be considered in rare clinical circumstances. These requests will be forwarded for Medical Director review
 - ◆ If discordant twins $\geq 20\%$. See practice note below. Twice weekly BPP plus ultrasound (CPT® 76816) every 2 to 4 weeks, **and** umbilical artery Doppler (CPT® 78620) weekly; for twice weekly imaging send to MD review
 - ◆ If FGR is diagnosed, weekly umbilical artery Doppler **and/or** Middle Cerebral Artery Doppler (CPT® 76820 and/or CPT® 76821)
 - ◆ If IVF dichorionic twins, report initial fetal echo as CPT® 76825 and/or CPT® 76827 and/or CPT® 93325. Transabdominal fetal echo is usually not performed prior to 16 weeks. Follow-up echo requests will be sent to Medical Director review
 - ◆ If other high risk factors, see: **OB-11: High Risk Pregnancy**

OB-16.3: For Known monochorionic-diamniotic or monochorionic-monoamniotic multiple pregnancies

For Known monochorionic-diamniotic or monochorionic-monoamniotic multiple pregnancies

- CPT® 76811 [plus CPT® 76812 if more than one fetus] if greater than 14 weeks if a complete detailed anatomic scan CPT® 76811 has not yet been performed during this pregnancy.
 - ◆ Ultrasound (CPT® 76816) every 2 to 4 weeks to assess fetal growth starting at 16 weeks gestation
 - ◆ Transvaginal ultrasound (CPT® 76817) is recommended only in twin gestation with significant cervical shortening ≤ 1.5 cm on a transabdominal evaluation if rescue cerclage is a consideration. Send all these requests to MD Review
 - ◆ Weekly BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST, starting at 32 weeks, sooner if additional risk factors are present.
 - ◆ Fetal middle cerebral artery (MCA) Doppler (CPT® 76821) every 2 to 3 weeks starting at 16 weeks to monitor for twin-twin transfusions syndrome (TTTS) and may be continued every 2 to 3 weeks to monitor for twin anemia polycythemia sequence (TAPS) until delivery. If Twin to Twin Transfusion syndrome is suspected due to one twin failing to grow compared with the other twin, daily evaluation (CPT® 76815), **and/or** CPT® 76818 or CPT® 76819 **and/or** umbilical artery Doppler (CPT® 76820) can be performed to aid in planning intervention and/or imminent delivery
 - ◆ If discordant twins $\geq 20\%$. See practice note below Twice weekly BPP plus ultrasound (CPT® 76816) every 2 to 4 weeks, **and** umbilical artery Doppler (CPT® 76820) weekly.
 - ◆ Daily fetal testing may be indicated if umbilical Doppler is abnormal. These requests will be forwarded for Medical Director for review.
 - ◆ Fetal echo CPT® 76825 and/or CPT® 76827 and/or CPT® 93325 for initial echo. Transabdominal fetal echo is usually not performed prior to 16 weeks. For follow-up echo, send to MD review.
 - ◆ If FGR is diagnosed, weekly umbilical artery Doppler CPT® 76820 and/or weekly Middle Cerebral Artery Doppler (CPT® 76821)
 - ◆ If other high risk factors, see **OB-11.1: High Risk Group One-Risk Factors**
- Triplets or higher Multiple Pregnancy receive same imaging as monochorionic-diamniotic- and monochorionic- monoamniotic- twins.
- These requests will be forwarded for Medical Director review.

Practice Notes

Discordant twins

Birth weight discordance = (larger twin weight minus smaller twin weight) divided larger twin weight $\times 100$.

Cervical Length Screening

Cervical length screening is not recommended in twin gestation. The use of a rescue cerclage when cervical dilation is present has been shown to be beneficial. For this reason, a cervical length under 1.5 cm is required for evaluation. In select cases, a TV ultrasound may be indicated. These require approval from the Medical Director. Cerclage is used in some cases of TTTS due to polyhydramnios causing the short

cervix. Also, rescue cerclage is still used in those with a dilated cervix.

Surviving fetus(es) in multifetal pregnancy complicated by demise of one fetus/fetal reduction:

- Fetal loss of one twin during the first trimester does not appear to increase the risk of FGR or preterm delivery in the surviving twin.
 - ◆ Loss for one fetus after 17 weeks gestation increases the risk of low birth weight and preterm delivery (compared to singleton pregnancies.) Multiple pregnancies affected by loss of one or more fetus(es) after 17 weeks or by fetal reduction should be imaged according to OB 16.
 - ◆ Monochorionic twin pregnancies with demise of one twin after 17 weeks have 17% chance of major morbidity or mortality for the remaining fetus, these cases should be sent for Medical Director review.

References

1. Practice Bulletin No. 169: Multiple gestations: twin triplet and higher order multi fetal pregnancies. 2016;128(4):e131-146. Obstetrics & Gynecology. Accessed November 16, 2017. http://journals.lww.com/greenjournal/Abstract/2016/10000/Practice_Bulletin_No_169_Multifetal_Gestations.59.aspx.
2. Practice Bulletin No. 175 Summary: Ultrasound in Pregnancy. Obstet Gynecol. 2016;128(6):1459-1460. Accessed November 3, 2017. http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx
3. Khalil A, Rodgers M, Baschat A, et al. ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Ultrasound Obstet Gynecol. 2016;47(2):247–263. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.15821/epdf>.
4. Slaghekke F, Pasman S, Veujoz M, et al. Middle cerebral artery peak systolic velocity to predict fetal hemoglobin levels in twin anemia-polycythemia sequence. Ultrasound Obstet Gynecol 2015; 46:432.
5. ACOG Practice Bulletin No. 130: Prediction and Prevention of Preterm Birth. October 2012, reaffirmed 2018.
6. ACOG Practice Bulletin No. 142: Cerclage for the management of cervical insufficiency. February 2014, reaffirmed 2016.
7. Rafael TJ, Berghella V, Alfirevic Z. Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy. Cochrane Database Syst Rev. 2014 Sep 10;(9):
8. Abbasi N, Barrett J, Melamed N. Outcomes following rescue cerclage in twin pregnancies(). J Matern Fetal Neonatal Med. 2018 Aug;31(16):2195-2201.
9. Jain D, Purohit RC. Review of Twin Pregnancies with Single Fetal Death: Management, Maternal and Fetal Outcome. Journal of Obstetrics and Gynaecology of India. 2014;64(3):180-183.
10. Razaz N, Avitan T, Ting J, Pressey T, Joseph KS. Perinatal outcomes in multifetal pregnancy following fetal reduction. CMAJ. 2017 May 8;189(18):E652-E658.
11. Practice Committee of American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril. 2012 Apr;97(4):825-34.
12. Lopriore E, Slaghekke F, Oepkes D, et al. Clinical outcome in neonates with twin anemia-polycythemia sequence. Am. J. Obstet. Gynecol. 2010; 203(1):54.e1-5. Accessed November 14, 2017. [http://www.ajog.org/article/S0002-9378\(10\)00245-0/fulltext?cc=y](http://www.ajog.org/article/S0002-9378(10)00245-0/fulltext?cc=y).
13. Slaghekke F, Kist WJ, Oepkes D, et al. Twin anemia-polycythemia sequence: diagnostic criteria, classification, perinatal management, and outcome. Fetal Diagn Ther. 2010;27(4):181-90. Accessed November 20, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/20339296>.
14. Suzuki S. Twin anemia-polycythemia sequence with placental arterio-arterial anastomoses. Placenta. 2010;31(7):652. Accessed November 14, 2017. [http://www.placentajournal.org/article/S0143-4004\(10\)00158-X/pdf](http://www.placentajournal.org/article/S0143-4004(10)00158-X/pdf).
15. Gucciardo L, Lewi L, Vaast P, et al. Twin anemia polycythemia sequence from a prenatal perspective. Prenat Diagn 2010;30(5):438-42. Accessed November 14, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/pd.2491/epdf>.

16. Weingertner AS, Kohler A, Kohler M, et al. Clinical and placental characteristics in four new cases of twin anemia-polycythemia sequence. *Ultrasound Obstet Gynecol*. 2010;35(4):490-4. Accessed November 14, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7508/abstract>
17. Khalil A, Rodgers M, Baschat A et al. ISUOG Practice Guidelines: role of ultrasound in twin pregnancies. *Ultrasound Obstet Gynecol* 2016;47(2):247–263. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.15821/epdf>.
18. Tollenaar LSA, Slaghekke F, Middeldorp JM, et al. Twin Anemia Polycythemia Sequence: Current Views on Pathogenesis, Diagnostic Criteria, Perinatal Management, and Outcome | *Twin Research and Human Genetics*. Cambridge Core. <https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S1832427416000189>. Published April 12, 2016. Accessed September 20, 2018.

OB-17: Previous C-section or History of Uterine Scar

OB-17.1: Previous C-section or history of uterine scar

73

OB-17.1: Previous C-section or history of uterine scar

If patient has had a previous Cesarean section and/or uterine scar	
➤	One ultrasound can be performed to confirm dates
➤	CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed, OR CPT® 76815 for limited ultrasound if complete ultrasound has already been performed, and/or CPT® 76817 for a transvaginal ultrasound indicated if less than 14 weeks
➤	CPT® 76805 for fetal anatomic scan is ideally performed between 18 to 20 weeks but must be performed after 16 weeks, if earlier send to MD Review
➤	One growth scan (CPT® 76816) at 32 weeks and one growth scan between 36 and 38 weeks (CPT® 76816)

References

1. Obed JY, Omigbodun A. Rupture of the uterus in patients with previous myomectomy and primary caesarean section scars: A comparison. Journal of Obstetrics and Gynaecology. 1996;16(1):16-21. doi:10.3109/01443619609028374.
2. Gyamfi-Bannerman C, Gilbert S, Landon MB, et al. Risk of Uterine Rupture and Placenta Accreta With Prior Uterine Surgery Outside of the Lower Segment. Obstetrics & Gynecology. 2012;120(6):1332-1337. doi:10.1097/aog.0b013e318273695b.

OB-18: Post Date Pregnancy

OB-18.1: Late-Term/Postterm Pregnancy

75

OB-18.1: Late-Term/Postterm Pregnancy

- | |
|--|
| ➤ Follow-up ultrasound (CPT® 76816) every 2 weeks ($\geq$ 40 weeks gestation) to evaluate fetal growth |
| ◆ Weekly biophysical profile (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST, starting at 40 weeks |
| ◆ Then twice weekly, BPP (CPT® 76818 or CPT® 76819) or CPT® 76815 for AFI with NST at 41 weeks or greater |

Practice Note

In post-date pregnancy, uterine artery Doppler velocimetry (CPT® 93976) has not been found to be useful.

Reference

1. Practice Bulletin No. 146: Management of Late-Term and Post-Term Pregnancies. Obstetrics & Gynecology. 2014;124(2):390-396, reaffirmed 2016. Accessed November 16, 2017.
http://journals.lww.com/greenjournal/Abstract/2014/08000/Practice_Bulletin_No_146_Management_of.34.aspx.

OB-19: Preterm/Prelabor Rupture of Membranes

OB-19.1: Current Preterm Prelabor Rupture of Membranes (PPROM)	77
---	-----------

OB-19.2: Current Prelabor Rupture of Membranes (PROM)	77
--	-----------

See also: **OB-4: Amniotic Fluid Abnormalities/ Oligohydramnios/ Polyhydramnios**

See also: **OB-13.2: Cerclage in place in current pregnancy**

OB-19.1: Current Preterm Prelabor Rupture of Membranes (PPROM)

- Less than or equal to 36 6/7 weeks. Requests will be forwarded to Medical Director review.
 - ◆ This is likely a hospital admission for evaluation and monitoring until delivery.
 - ◆ In rare cases, outpatient monitoring has been performed (refer to Medical Director for review)

OB-19.2: Current Prelabor Rupture of Membranes (PROM)

- Greater than or equal to 37 weeks. Requests will be forwarded to Medical Director for review.
 - ◆ This will likely result in a hospital admission for delivery

References

1. Practice Bulletin No. 130: Prediction and Prevention of Preterm Birth. Obstetrics & Gynecology. 2012;120(4):964-973, reaffirmed 2018. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Citation/2012/10000/Practice_Bulletin_No_130_Prediction_and.42.aspx.
2. Practice Bulletin No. 172: Premature Rupture of Membranes. Obstet Gynecol. 2016 Oct;128(4):e165-77. Accessed November 16, 2017. <http://journals.lww.com/greenjournal/Pages/articleviewer.aspx?year=2016&issue=10000&article=00062&type=Fulltext>.
3. Practice Bulletin No. 171: Management of Pre-term Labor. Obstetrics & Gynecology. October 2016;128(4):e155–64. Replaces Practice Bulletin Number 159, January 2016 (Interim Update) Accessed November 16, 2017. <https://www.medscape.com/medline/abstract/27661654>.

OB-20: Third Trimester Imaging

OB-20.1: Third Trimester Imaging - Ultrasound

79

OB-20.1: Third Trimester Imaging – Ultrasound

Imaging in the third trimester is indicated for bleeding, pain, absent fetal heart tone, decreased fetal movement and/or other high-risk indications.

(see: **OB-11: High Risk Pregnancy**)

For suspected breech position, see: **OB-2: Abnormal Fetal Position or Presentation**

Reference

1. Practice Bulletin No. 175 Summary: Ultrasound in pregnancy. Obstet & Gynecol. 2016;128(6):1459-1460. Accessed November 3, 2017.
http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.

OB-21: Uncertain Dates

OB-21.1: Uncertain Dates/Unknown Last Menstrual Period (LMP) 81

OB-21.1: Uncertain Dates/Unknown Last Menstrual Period(LMP)

- The **low-risk pregnancy** that has no other indications for ultrasound should have a fetal anatomic ultrasound (CPT® 76805) performed at 16 weeks or greater. The timing can be determined by fundal height. (See: **OB-5: Fetal Anatomic Scan**).
- If there is a difference between the clinical size of the uterus on pelvic exam and the projected gestational age **and** the date of the last menstrual period is uncertain or there have been irregular periods in the past year, one ultrasound can be performed to confirm dates:
 - ◆ (CPT® 76801) [plus CPT® 76802 if more than one fetus] and/or CPT® 76817 for a transvaginal ultrasound if less than 14 weeks and a complete ultrasound has not yet been performed
 - ◆ CPT® 76805 (plus CPT® 76810 if more than one fetus) if equal to or greater than 14 weeks when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed.
 - ◆ CPT® 76815

References

1. Practice Bulletin No. 175 Summary: Ultrasound in pregnancy. Obstet & Gynec. 2016;128(6):1459-1460. Accessed November 16, 2017.
http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.
2. Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society of Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. Obstet Gynecol Survey. 2014; 69(8):453-455. Accessed November 16, 2017.
http://journals.lww.com/obgynsurvey/Abstract/2014/08000/Fetal_Imaging_Executive_Summary_of_a_Joint.4.aspx.

OB-22: Unequal Fundal Size and Dates

OB-22.1: Unequal Fundal Size and Dates

83

OB-22.1: Unequal Fundal Size and Dates

First trimester early second trimester

- If there is a difference between the clinical size of the uterus on pelvic exam and the projected gestational age.
 - ◆ In the first trimester: (CPT® 76801) [plus CPT® 76802 if more than one fetus] and/or CPT® 76817 for a transvaginal ultrasound if less than 14 weeks and a complete ultrasound has not yet been performed or 76815
 - ◆ Between 14 and 23 weeks: CPT® 76805 (plus CPT® 76810 if more than one fetus) if equal to or greater than 14 weeks when complete fetal anatomic scan CPT® 76805 is planned and has not yet been performed.

Unequal fundal size is defined as more than a 3 week difference in fundal height and gestational age at **23 weeks gestation or greater**.

- One ultrasound can be performed (CPT® 76805) if complete fetal anatomic scan is planned and has not been performed or CPT® 76816 if CPT® 76805 complete anatomic scan or detailed ultrasound CPT® 76811 has been done previously.

References

1. Pay A, Frøen J, Staff A, Jacobsson B, Gjessing H. Prediction of small-for-gestational-age status by symphysis-fundus height: a registry-based population cohort study. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2015;123(7):1167-1173. doi:10.1111/1471-0528.13727.
2. Pay ASD, Wiik J, Backe B, Jacobsson B, Strandell A, Klovning A. Symphysis-fundus height measurement to predict small-for-gestational-age status at birth: a systematic review. *BMC Pregnancy and Childbirth*. 2015;15(1). doi:10.1186/s12884-015-0461-z .
3. American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. *Obstetrics & Gynecology*. 2013;121(5):1122-1133. Reaffirmed in 2018. doi:10.1097/01.aog.0000429658.85846.f9.

OB-23: Adnexal mass/Uterine Fibroids and Uterine Anomalies

OB-23.1: Adnexal Mass	85
OB 23.2: Uterine fibroids in pregnancy	85
OB 23.3: Uterine anomalies in pregnancy	86

OB-23.1: Adnexal Mass

➤ Ultrasound can be performed for a known or suspected adnexal/pelvic mass.
◆ First trimester: CPT® 76801 [plus CPT® 76802 if more than one fetus] and/or CPT® 76817 for a transvaginal ultrasound to establish dates ◆ If a complete ultrasound was done previously CPT® 76815 and/or CPT® 76817 for a transvaginal ultrasound.
◆ Second or third trimester: CPT® 76805 [plus CPT® 76810 if more than one fetus] if a complete fetal anatomic scan has not yet been performed, or CPT® 76815 or CPT® 76816 if a complete fetal anatomic scan was done previously.
➤ Following the initial ultrasound, follow up can be done once in each trimester, ◆ CPT® 76805 [plus CPT® 76810 if more than one fetus] if a complete fetal anatomic scan has not yet been performed, or ◆ CPT® 76815 or CPT® 76816 if a complete fetal anatomic scan was done previously.
➤ MRI pelvis (CPT 72195) without contrast can be done if additional imaging is needed due to indeterminate findings of possible dermoid or endometrioma on ultrasound, or for suspected malignancy
➤ See PV-5: Adnexal Mass/Ovarian Cysts

Practice note:

The majority of adnexal mass in pregnancy are benign, the most common diagnoses are mature teratomas and corpus luteum or paraovarian cysts. Malignancy is reported in only 1.2-6.8% of pregnant patients with persistent mass.

Levels of CA-125 are elevated in pregnancy, a low-level elevation in pregnancy is not typically associated with malignancy.

OB 23.2: Uterine fibroids in pregnancy

- If more than one fibroid, total size of all fibroids should be used, ie-one fibroid at 2 cm and one 3 cm is total of 5 cm and imaging would be indicated as below:
 - ◆ Moderate (over 5 cm) and large (over 10 cm) fibroid(s):
 - First trimester: CPT® 76801 [plus CPT® 76802 if more than one fetus] and/or CPT® 76817 for a transvaginal ultrasound to establish dates
 - Fetal anatomic scan at 16 weeks or greater (CPT® 76805 or if meets criteria in OB-11: High Risk Pregnancy— CPT® 76811)
 - Starting after the fetal anatomic scan at 16 weeks or greater, if the fibroid is in the lower uterine segment or cervical fibroid then ultrasound (CPT® 76815) every 2 to 4 weeks and/or transvaginal ultrasound (CPT® 76817) every 2 weeks until 24 weeks
 - Ultrasound (CPT® 76816) for growth at 24 weeks and then every 3 to 6 weeks.

Practice Note

The true incidence of fibroids during pregnancy is unknown. The reported rates vary from as low as 0.1% of all pregnancies to higher rates of 12.5%. It seems that pregnancy has little or no effect on the overall size of fibroids despite the occurrence of red degeneration in early pregnancy. Fibroids, however, affect pregnancy and delivery in several ways, with abdominal pain, miscarriage, malpresentation, and difficult delivery being the most frequent complications. The major concerns occur late in pregnancy. These complications relate to preterm labor, placental abruption, fetal growth restriction, and fetal compression syndromes. The risk of preterm labor appears to correlate with the size of the fibroid (over 600 cm³) and/or the presence of multiple fibroids. Placental abruption has been reported to occur frequently in pregnancies complicated by fibroids.

Placentation over a fibroid appears to be a strong risk factor for abruption. There does not appear to be any association of fetal growth restriction with small fibroids. However, when the fibroid volume is >200 cm³ fetal growth restriction appears more commonly. Fetal compression syndrome is a direct result of large fibroids and is not associated with commonly found small fibroids. Finally, malposition or obstructed labor is associated with fibroids of the lower uterine segment.

OB 23.3: Uterine anomalies in pregnancy

For uterine septum, uterine didelphys, unicornuate uterus, bicornuate uterus one ultrasound can be performed to confirm dates:

- Ultrasound CPT® 76801 [plus CPT® 76802 if more than one fetus] if a complete ultrasound has not yet been performed once in first trimester, or CPT® 76815 for limited ultrasound if a complete ultrasound CPT® 76801 has already been performed and/or CPT® 76817 for transvaginal ultrasound once in first trimester (less than 14 weeks)
- Ultrasound is supported at 16 weeks or greater: CPT® 76805 [plus CPT® 76810 if more than one fetus] if a complete detailed fetal anatomic scan has not been done and/or CPT® 76817
- Starting after the fetal anatomic scan at 16 weeks or greater, ultrasound (CPT® 76815) every 2 to 4 weeks and/or transvaginal ultrasound (CPT® 76817) every 2 weeks until 24 weeks
- Starting at 23 to 24 weeks, follow-up growth scans (CPT® 76816) every 3 to 6 weeks
- Starting at 32 weeks, weekly BPP (CPT® 76818 or CPT® 76819) or AFI (CPT® 76815) with NST

References

1. Qidwai GI, Caughey AB, and Jacoby AF. Obstetric outcomes in women with sonographically identified uterine leiomyomata. *Obstet Gynecol.* 2006;22(2):114. Accessed November 16, 2017. http://journals.lww.com/ultrasound-quarterly/Citation/2006/06000/Obstetric_Outcomes_in_Women_with_Sonographically.10.aspx.
2. Laughlin SK, Baird DD, Savitz DA, et al. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. *Obstet Gynecol.* 2009; 113(3):630-635. Accessed November 16, 2017. <https://insights.ovid.com/pubmed?pmid=19300327>.
3. Stout MJ, Odibo AO, Graseck AS, et al. Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes. *Obstet Gynecol.* 2010;116(5):1056. Accessed November 16, 2017. <http://www.fibroidsecondopinion.com/2010/11/fibroids-leiomyomas-at-routine-second-trimester-ultrasound-examination-and-adverse-obstetric-outcomes/>.
4. Klatsky PC, Tran ND, Caughey AB, et al. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. *Am J Obstet Gynecol.* 2008;198(4):357-66. Accessed November 16, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/18395031>.
5. Lee HJ, Norwitz ER, and Shaw J. Contemporary Management of Fibroids in Pregnancy. *Reviews in Obstetrics and Gynecology.* 2010;3(1):20-27. Accessed November 16, 2017. <https://www.scribd.com/document/329485720/Contemporary-Management-of-Fibroids-in-Pregnancy>
6. Nick AM, Schmeler, K. Adnexal Masses in Pregnancy. *Perinatology.* 2010; 2:13-21.
7. Practice Bulletin No. 174. Evaluation and management of adnexal masses. *Obstet Gynecol.* 2016 Nov;128(5):1193-1195. (November 2016). Accessed October 5, 2017. http://journals.lww.com/greenjournal/Abstract/2016/11000/Practice_Bulletin_No_174_Summary_Evaluation_and.47.aspx.
8. Stout M, Odibo A, Graseck A, et al. Leiomyomas at Routine Second-trimester Ultrasound Examination and Adverse Obstetric Outcomes. *Obstetric Anesthesia Digest.* 2012;32(1):21-22. doi:10.1097/01.aoa.0000410780.41686.41
9. Shavell VI, Thakur M, Sawant A, et al. Adverse obstetric outcomes associated with sonographically identified large uterine fibroids. *Fertil Steril.* 2012;97(1):107–110
10. Kase BA, Blackwell SC. SMFM consult: Fibroids in pregnancy: Meaning and Management. *Contemporary OBGYN.* <http://www.contemporaryobgyn.net/modern-medicine-feature-articles/smf-consult-fibroids-pregnancy-meaning-and-management>. Published December 5, 2014. Accessed September 14, 2018.
11. ACOG Practice Bulletin No. 142: Cerclage for the management of cervical insufficiency. February 2014, reaffirmed 2016.
12. Hua M, Odibo AO, Longman RE, Macones GA, Roehl KA, Cahill AG. Congenital uterine anomalies and adverse pregnancy outcomes. *American Journal of Obstetrics and Gynecology.* 2011;205(6). doi:10.1016/j.ajog.2011.07.022
13. Fox NS, Roman AS, Stern EM, et.al. Type of congenital uterine anomaly and adverse pregnancy outcomes. *The Journal of Maternal-Fetal & Neonatal Medicine.* 2013;27(9):949-953. doi:10.3109/14767058.2013.847082.
14. Blitz MJ, Rochelson B, Augustine S, Greenberg M, Sison CP, Vohra N. *J Matern Fetal Neonatal Med.* 2016 Nov;29(21):3454-60. doi: 10.3109/14767058.2015.1131261. Epub 2016 Jan 14. PMID: 26653679

OB-24: Procedure Coding Basics for Established Pregnancy

Procedure Coding Basics for Established Pregnancy General Considerations	89
OB-24.1: OB Ultrasound Code Selection	90
OB-24.2: Required Elements for First Trimester OB Ultrasound	91
OB-24.3: Required Elements for Second or Third Trimester Fetal Anatomic Evaluation OB Ultrasound	92
OB-24.4: Required Elements for a Detailed Fetal Anatomic Evaluation OB Ultrasound	94
OB-24.5: Fetal Nuchal Translucency	97
OB-24.6: Limited and Follow-Up Studies	98
OB-24.7: Obstetric Transvaginal Ultrasound	99
OB-24.8: Biophysical Profile (BPP)	99
OB-24.9: Fetal Doppler	100
OB-24.10: Duplex Scan (Uterine Artery)	102
OB-24.11: Fetal Echocardiography	104
OB-24.12: 3D and 4D Rendering	105
OB-24.13: Fetal MRI	106

Procedure Coding Basics for Established Pregnancy General Considerations

A Duplex scan describes:

1. An ultrasonic scanning procedure for characterizing the pattern and direction of blood flow in arteries and veins with the production of real-time images integrating B-mode two dimensional vascular structure, and
2. Doppler spectral analysis, and
3. Color flow Doppler imaging

The use of a hand-held or any Doppler device that does not create a hard-copy output is considered part of the physical examination and is not separately billable. This exclusion includes devices that produce a record that does not permit analysis of bi-directional vascular flow.

The minimal use of color Doppler alone, when performed for anatomical structure identification, during a standard ultrasound procedure, is not separately reimbursable.

- All obstetric ultrasound studies require permanently recorded images:
 - ◆ These images may be stored on film or in a Picture Archiving and Communication System (PACS).
 - ◆ Obstetric ultrasound services may not be billed without image recording.
 - ◆ The use of a hand-held or any Doppler device that does not create a hard-copy output is considered part of the physical examination and is not separately reimbursable.
- Ultrasound procedure codes include the preparation of a required final written report which should be included in the patient's medical record.
 - ◆ Each procedure code has specific required elements which are described in this section.
 - ◆ The report should document the results of the evaluation of each element or the reason any element is non-visualized.
 - ◆ Documentation of less than the required elements requires the billing of the "limited" code for that anatomic region.
 - ◆ Only one (1) limited exam may be billed per encounter.

OB-24.1: OB Ultrasound Code Selection

It is not appropriate to report non-obstetrical pelvic ultrasound procedure codes (CPT® 76830, CPT® 76856, and CPT® 76857) if pregnancy has already been diagnosed.

CPT® Code Guidance	
The OB ultrasound CPT® codes should be selected based on the following criteria.	
➤ The length of gestation:	◆ CPT® 76801 and CPT® 76802 are reported for complete studies performed during the first trimester (< 14 weeks). ◆ CPT® 76801 and CPT® 76802 should only be used once per pregnancy unless the mother changes to a new medical caregiver at a new office and there is a medical indication for ultrasound. ◆ CPT® 76805 and CPT® 76810 are used to report complete studies (anatomy scan) performed during the second and third trimester. ◆ CPT® 76805 and CPT® 76810 should only be used once per pregnancy unless the mother changes to a new medical caregiver at a new office and there is a medical indication for ultrasound.
➤ The number of fetuses:	◆ CPT® 76802, CPT® 76810, CPT® 76812, and CPT® 76814 are “add-on” codes used to report each additional fetus.
➤ The imaging approach:	◆ CPT® 76817 is used to report a transvaginal ultrasound. The other OB ultrasound codes are used for transabdominal studies.
➤ Whether the study is Complete or Limited:	◆ CPT® 76816 is used to report follow up studies requiring more information, such as growth scans or follow up on anatomy when more than one area is examined. ◆ CPT® 76815 is used to report limited follow-up studies.
➤ Whether a detailed fetal anatomic evaluation is performed:	◆ CPT® 76811 and CPT® 76812 describe an extensive fetal ultrasound evaluation and detailed anatomic survey and are used only when the study includes this service. ◆ CPT® 76812 is an add-on for each additional fetus. ◆ Any follow-up ultrasound for CPT® 76811 should be coded as CPT® 76816

OB-24.2: Required Elements for First Trimester OB Ultrasound

- Determination of the number of gestational sacs and fetuses
- Gestational sac/fetal measurements appropriate for gestation (< 14 weeks)
- Survey of visible fetal anatomic structures and placental evaluation when possible
- Qualitative assessment of amniotic fluid volume/gestational sac shape
- Examination of maternal uterus and adnexa

A complete first-trimester transabdominal ultrasound (CPT® 76801 and CPT® 76802) is defined in CPT® as including the following elements:

CPT® Code Guidance
It may not be possible to visualize the placenta during the early weeks of pregnancy. CPT® 76801 and/or CPT® 76802 may still be appropriately billed if the report documentation indicates placental anatomic structure could not be evaluated due to gestational age.
CPT® 76802 is an 'add-on' code reported in conjunction with the 'primary procedure' CPT® 76801 to report each additional gestation.
CPT® 76801 and CPT® 76802 should only be reported once per pregnancy unless the mother changes to a new medical caregiver at a new office and there is a medical indication for ultrasound. Follow-up studies to CPT® 76801 and CPT® 76802 should be reported as CPT® 76815

OB-24.3: Required Elements for Second or Third Trimester Fetal Anatomic Evaluation OB Ultrasound

CPT® Code Guidance

A complete second or third trimester transabdominal ultrasound (CPT® 76805 and CPT® 76810) is defined in CPT® as including the following elements:

- ◆ Head, face, and neck
- ◆ Lateral cerebral ventricles;
- ◆ Choroid plexus;
- ◆ Midline falx;
- ◆ Cavum septi pellucidi;
- ◆ Cerebellum;
- ◆ Cistern magna; and
- ◆ Upper lip
- ◆ A measurement of the nuchal fold may be helpful during a specific age interval to assess the risk of aneuploidy.
- ◆ Chest/Heart
- ◆ Four-chamber view;
- ◆ Left ventricular outflow tract; and
- ◆ Right ventricular outflow tract.
- ◆ Abdomen:
- ◆ Stomach (presence, size, and situs);
- ◆ Kidneys;
- ◆ Urinary bladder;
- ◆ Umbilical cord insertion site into the fetal abdomen; and
- ◆ Umbilical cord vessel number.
- ◆ Spine:
- ◆ Cervical, thoracic, lumbar, and sacral spine.
- ◆ Extremities:
- ◆ Legs and arms.
- ◆ Genitalia:
- ◆ In multiple gestations and when medically indicated
- ◆ Placenta
- ◆ Location
- ◆ Relationship to internal os
- ◆ Appearance
- ◆ Placental cord insertion (when possible)
- ◆ Standard evaluation
- ◆ Fetal number
- ◆ Presentation
- ◆ Qualitative or semi-qualitative estimate of amniotic fluid
- ◆ Maternal anatomy
- ◆ Cervix (transvaginal if cervical length is ≤ 3 cm)
- ◆ Uterus
- ◆ Adnexa
- ◆ Biometry
- ◆ Biparietal diameter
- ◆ Head circumference
- ◆ Femur length
- ◆ Abdominal circumference

◆ Fetal weight estimate

CPT® 76810 is an 'add-on' code used with the 'primary procedure' CPT® 76805 to report each additional gestation.

CPT® 76805 and CPT® 76810 **should only be used once per pregnancy** unless the mother changes to a new medical caregiver at a new office and there is a medical indication for ultrasound. Follow-up studies to CPT® 76805 and CPT® 76810 should be coded as CPT® 76815 or CPT® 76816.

References

1. Practice Bulletin No. 130 Prediction and prevention of pre-term birth. Obstetrics & Gynecology, reaffirmed 2018. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Citation/2012/10000/Practice_Bulletin_No_130_Prediction_and.42.aspx.
2. Cho, H.J. and Roh H.J. Correlation between cervical lengths measured by transabdominal and transvaginal sonography for predicting preterm birth. Journal of Ultrasound in Medicine. 2016;35:537–544. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.7863/ultra.15.03026/epdf>.
3. McIntosh J, Feltovich H, Berghella V, et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. American Journal of Obstetrics and Gynecology. 2016;215(3):B2-B7. Accessed November 15, 2017. [http://www.ajog.org/article/S0002-9378\(16\)30112-0/fulltext](http://www.ajog.org/article/S0002-9378(16)30112-0/fulltext).
4. Khalifeh Adeeb, Vincenzo Berghella, David Stamilio, et al. Ultrasound approach for cervical length screening in preterm birth prevention. American Journal of Obstetrics & Gynecology. Dec 2016;215(6) 739-744.
5. ACOG Practice Bulletin 175. Ultrasound in Pregnancy, 2016. Summary. Obstetrics & Gynecology. 2016; 128(6):1459-1460. doi:10.1097/aog.0000000000001812
6. Esplin MS, Elovitz MA, Iams JD, et al. Predictive accuracy of serial transvaginal cervical lengths and quantitative vaginal fetal fibronectin levels for spontaneous preterm birth among nulliparous women. JAMA. 2017;317(10):1047-1056. Accessed December 6, 2017. <https://www.rtihs.org/sites/default/files/28462%20Hunter%202017%20Predictive%20accuracy%20of%20serial%20transvaginal%20cervical%20lengths%20and%20quantitative%20vaginal%20fetal%20fibronectin%20levels%20for%20spontaneous%20preterm%20birth%20among%20nulliparous%20women.pdf>.
7. Jain S, Kilgore M, Edwards RK, et al. Revisiting the cost-effectiveness of universal cervical length screening: importance of progesterone efficacy. A J Obstet Gynecol. 2016 Jul;215(1):101.e1-101.e7. Accessed December 6, 2017. [http://www.ajog.org/article/S0002-9378\(16\)00215-5/fulltext](http://www.ajog.org/article/S0002-9378(16)00215-5/fulltext)

OB-24.4: Required Elements for a Detailed Fetal Anatomic Evaluation

OB Ultrasound

CPT® Code Guidance
Performance of the specialized fetal anatomic evaluation (CPT® 76811 and CPT® 76812) should be limited to those with special skills to perform this study, such as Maternal Fetal Medicine specialists, Perinatologists, and Radiologists (with advanced training in fetal imaging) .
CPT® 76811 and CPT® 76812 are defined in CPT® as including all of the requirements listed for CPT® 76805 and CPT® 76810. In addition, the report must document detailed anatomic evaluation of the following elements: ◆ Head, face, and neck ◆ 3rd ventricle ◆ 4th ventricle ◆ Lateral ventricles ◆ Cerebellar lobes, vermis, and cisterna magna ◆ Corpus callosum ◆ Integrity and shape of cranial vault ◆ Brain parenchyma ◆ Neck ◆ Profile ◆ Coronal face (nose/lips/lensa) ◆ Palate, maxilla, mandible, and tongue ◆ Ear position and size ◆ Orbits ◆ Chest/Heart ◆ Aortic arch ◆ Superior and inferior vena cava ◆ 3-vessel view ◆ 3-vessel and trachea view ◆ Lungs ◆ Integrity of diaphragm ◆ Ribs ◆ Abdomen: ◆ Small and large bowel ◆ Adrenal glands ◆ Gallbladder ◆ Liver ◆ Renal arteries ◆ Spleen ◆ Integrity of abdominal wall ◆ Spine: ◆ Integrity of spine and overlying soft tissue ◆ Shape and curvature ◆ Extremities: ◆ Number: architecture and position ◆ Hands ◆ Feet ◆ Digits: number and position ◆ Genitalia

CPT® Code Guidance

- ◆ Sex
- ◆ Placenta
- ◆ Masses
- ◆ Placental cord insertion
- ◆ Accessory/succenturiate lobe with location of connecting vascular supply to primary placenta
- ◆ Biometry
- ◆ Cerebellum
- ◆ Inner and outer orbital diameters
- ◆ Nuchal thickness (16 to 20 wk)
- ◆ Nasal bone measurement (15 to 22 wk)
- ◆ Humerus
- ◆ Ulna/radius
- ◆ Tibia/fibula
- ◆ Maternal Anatomy
- ◆ Cervix (transvaginal if cervical length is ≤ 3.0 cm)
- ◆ Uterus
- ◆ Adnexa

- CPT® 76812 is an 'add-on' code used with the 'primary procedure' CPT® 76811 to report each additional gestation.
 - ◆ These studies are usually performed at 18 to 20 weeks and are most often completed at tertiary referral centers with perinatology departments.
 - ◆ Only one medically indicated procedure CPT® 76811 per pregnancy, per practice (per NPI) is appropriate. *Follow-up studies should be coded as CPT® 76815 or CPT® 76816

References

1. Practice Bulletin No.130: Prediction and prevention of pre-term birth. Obstetrics & Gynecology. 2012;120(4):964-973 reaffirmed 2016. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Citation/2012/10000/Practice_Bulletin_No_130_Prediction_and.42.aspx.
2. Wax J, Minkoff H, Johnson A, et al. Consensus report on detailed fetal anatomic ultrasound anatomic ultrasound examination indications, components, and qualifications. Journal of Ultrasound in Medicine. 2014;33(2):189-195. Accessed November 15, 2017. http://api.ning.com/files/cZ399qCqOaHeuZzVLVyhIBxiUetrbLYKO3Bw9Tt6vH2VZjNDiuNoRV*TfNUrqT5k4qdLfS6J8OIAGmAHfkKiXIDZdpW4U1-u/consensus768112014.pdf.
3. Practice Bulletin No. 175 Summary: Ultrasound in Pregnancy. Obstet Gynecol. 2016;128(6):1459-1460. Accessed November 3, 2017. http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.
4. Cho, H.J. and Roh, H.J. Correlation between cervical lengths measured by transabdominal and transvaginal sonography for predicting preterm birth. Journal of Ultrasound in Medicine. 2016;35:537–544. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.7863/ultra.15.03026/epdf>.
5. McIntosh J, Feltovich H, Berghella V, et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. American Journal of Obstetrics and Gynecology. 2016; 215(3):B2-B7. Accessed November 15, 2017. [http://www.ajog.org/article/S0002-9378\(16\)30112-0/fulltext](http://www.ajog.org/article/S0002-9378(16)30112-0/fulltext).
6. Khalifeh, Adeeb, Vincenzo Berghella, et al. Ultrasound approach for cervical length screening in preterm birth prevention. American Journal of Obstetrics & Gynecology. Dec 2016;215(6),739-744 739.
7. Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging executive summary of A Joint Eunice Kennedy Shriver National Institute Of Child Health and Human Development. Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology and Society of Radiologists in Ultrasound Fetal Imaging Workshop. J Ultrasound Med. 2014;33:745-757.
8. Esplin MS, Elovitz MA, Iams JD, et al. Predictive accuracy of serial transvaginal cervical lengths and quantitative vaginal fetal fibronectin levels for spontaneous preterm birth among nulliparous women. JAMA. 2017;317(10):1047-1056. Accessed December 6, 2017. <https://www.rtihs.org/sites/default/files/28462%20Hunter%202017%20Predictive%20accuracy%20of%20serial%20transvaginal%20cervical%20lengths%20and%20quantitative%20vaginal%20fetal%20fibronectin%20levels%20for%20spontaneous%20preterm%20birth%20among%20nulliparous%20women.pdf>.
9. Jain S, Kilgore M, Edwards, RK, et al. Revisiting the cost-effectiveness of universal cervical length screening: importance of progesterone efficacy. A J Obstet Gynecol. 2016 Jul;215(1):101.e1-101.e7. Accessed December 6, 2017. [http://www.ajog.org/article/S0002-9378\(16\)00215-5/fulltext](http://www.ajog.org/article/S0002-9378(16)00215-5/fulltext)

OB-24.5: Fetal Nuchal Translucency

CPT® Code Guidance

- CPT® 76813 and CPT® 76814 describe ultrasound measurement of the clear (translucent) space at the back of the fetal neck to assess risk for Down Syndrome (Trisomy 21), Trisomy 18, and other genetic disorders.
 - ◆ NT is performed when the crown rump length 44-83 mm. This is typically at a gestational age of approximately 11 to 13 6/7 weeks
 - ◆ CPT® 76813 can be performed if the CRL measures between 44-83mm regardless of gestational age
 - ◆ Biochemistry testing is 10 to 14 weeks
- The sonographer performing the study and the physician interpreting the study must be credentialed by the Maternal Fetal Medicine Foundation or Nuchal Translucency Quality Review Program (NTQR).
 - ◆ CPT® 76814 is an add-on for each additional fetus.
- The first trimester screening is typically done between 11 and 13 6/7 weeks (CRL between 44 and 83 millimeters); abnormal Fetal Nuchal Translucency scan (if ≥ 2.5 mm there is an increased risk for aneuploidy, imaging should be based upon the MOM for NT and biochemical markers, ≥ 3 mm increased risk for cardiac defects, abdominal wall defects, diaphragmatic hernia, and genetic syndromes in euploid fetuses) during current pregnancy.

Practice Note

Required elements of the 76813 ultrasound code include:

- Fetal crown-rump measurement
- Observation of fetal cardiac activity
- Observation of the embryo at high magnification until the embryonic neck is in a neutral position and spontaneous embryonic movement allows for differentiation between the outer edge of the nuchal skin and the amnion
- At least three separate measurements of the largest distance between the inner borders of the fetal nuchal translucency
- Comparison of the largest nuchal translucency measurement from an acceptable image to crown-rump length and gestational age-specific medians
- Written documentation of each component of the examination and permanent documentation of ultrasound images.

The use of ultrasound codes (CPT® 76801/ CPT® 76802) should be indication driven and should not be routinely done whenever an ultrasound for nuchal translucency (CPT® 76813/ CPT® 76814) is requested. In cases where there is either a maternal and/or fetal indication, then the CPT® 76801 code can indeed be billed along with the nuchal translucency screening (CPT® 76813/ CPT® 76814).

References

1. Society for Maternal and Fetal Medicine (SMFM), coding committee. SMFM Coding Committee White Paper: Billing of 76801 and/or 76813 with cfDNA . October 2017 .

OB-24.6: Limited and Follow-Up Studies

CPT® Code Guidance

- **CPT® 76815** describes a **limited** or “quick look” study used to report one or more of the elements listed in the code definition, i.e. “fetal heartbeat”, placental location or fluid check (re: modified BPP which is NST with CPT® 76815)
 - ◆ Reported only once, regardless of the number of fetuses, and only once per date of service
 - ◆ CPT® 76815 should never be reported with complete studies CPT® 76801/ CPT® 76802 and CPT® 76805/ CPT® 76810.
- ◆ **CPT® 76816** describes a **follow-up** ultrasound (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), trans-abdominal approach, per fetus.
 - ◆ The use of this CPT code is reserved for subsequent follow up ultrasound only; i.e. An ultrasound must have been performed previously.
 - ◆ Components include: Focused assessment of fetal size by measuring BPD, abdominal circumference, femur length, or other appropriate measurement; and amniotic fluid volume
 - ◆ Detailed re-examination of a specific organ or system known or suspected to be abnormal
 - ◆ CPT® 76816 should be reported once per fetus evaluated in follow-up.
 - ◆ Modifier -59 is appropriately used on subsequent codes. For example, a follow-up of a twin pregnancy is reported: CPT® 76816 and CPT® 76816-59.
 - ◆ CPT® 76816 should never be reported with complete studies CPT® 76801, CPT® 76802 and CPT® 76805, CPT® 76810.
 - ◆ CPT® 76816 should not be performed prior to a CPT® 76801 and/or an anatomy scan CPT® 76805 (normal pregnancy) or Detailed anatomy scan CPT® 76811 (high risk pregnancy).

OB-24.7: Obstetric Transvaginal Ultrasound

CPT® Code Guidance
CPT® 76817 is used to report an obstetrical transvaginal ultrasound.
CPT® 76817 is reported only once regardless of the number of fetuses.
Although an obstetrical transvaginal ultrasound and transabdominal ultrasound can be performed at the same sitting and reported as two codes, there is rarely a medical indication to perform both studies at once.

OB-24.8: Biophysical Profile (BPP)

- The BPP combines data from ultrasound imaging and fetal heart rate (FHR) monitoring and is designed to predict the presence or absence of fetal asphyxia and, ultimately the risk of fetal death in the antenatal period (appropriately performed > 24 weeks; should NOT be performed prior to the time when the fetus would be viable outside of the uterus).
- Typically all components of the BPP, such as breathing, are not present until 26 weeks gestation. However, BPP may be utilized below 26 weeks in cases of FGR (with Doppler studies). The following parameters are evaluated:
 - ◆ Fetal breathing movements
 - ◆ Gross fetal body movements
 - ◆ Fetal tone
 - ◆ Qualitative amniotic fluid volume, at least one vertical pocket 2 x 2 cm
 - ◆ Reactive FHR (non-stress testing portion)

CPT® Code Guidance
CPT® 76818 includes non-stress testing.
CPT® 76819 does not include the non-stress testing portion.
If non-stress testing is performed without BPP, the appropriate code to use is CPT® 59025 (Fetal non-stress test). CPT® 59025 should not be reported with codes CPT® 76818 or CPT® 76819.
Although obstetrical ultrasound (CPT® codes: CPT® 76805, CPT® 76810, CPT® 76815, CPT® 76816, CPT® 76820) and BPP (CPT® 76818 and CPT® 76819) can be performed at the same sitting and reported as two codes, it is generally not necessary to perform both studies at once. ◆ There are certain clinical circumstances in which it would be medically indicated to perform both studies at once. ◆ Each study must have separate images, interpretations, and reports
BPP and/or non-stress testing, performed on more than one fetus, should be reported separately. The use of modifier -59 on the second and subsequent studies is appropriate, depending on payer policy.

Practice Note

If BPP ≤ 6, repeat BPP in 24 hours

OB-24.9: Fetal Doppler

CPT® Code Guidance

- CPT® 76820 describes Doppler velocimetry of the umbilical artery
 - ◆ Utilized for known FGR; see: **OB-8.1 Fetal Growth Restriction Current Pregnancy** and known oligohydramnios See: **OB-4.1 Amniotic Fluid Abnormalities**, and is typically performed > 22 weeks gestation. It may also be indicated with known twin to twin transfusion or known discordant twins (See: **OB-16 Multiple Pregnancies**) Its use to predict preeclampsia, and stillbirth is considered investigational.
- CPT® 76821 describes Doppler velocimetry of the middle cerebral artery.
- MCA Doppler (CPT® 76821), starting at 34 weeks, if Doppler CPT® 76820 is normal.
 - ◆ Performed as a substitute for amniocentesis to evaluate a fetus at risk for anemia due to Rhesus isoimmunization/alloimmunization, Twin anemia polycythemia sequence and non-immune hydrops caused by parvovirus B19 infection or any other known acquired or congenital cause of fetal anemia. See **OB-3.1 Alloimmunization/RH Isoimmunization/Other Causes of Fetal Anemia -3.4 Fetal Hydrops Associated with Polyhydramnios**; and **OB-16: Multiple Pregnancies**

Practice Notes

- Middle Cerebral Artery Doppler (MCA): Doppler flow studies of the MCA are used in the assessment of the fetus at risk for anemia see: **OB-3: Alloimmunization/RH Isoimmunization/Other Causes of Fetal Anemia/Parvo/Hydrops** and monochorionic twin pregnancies see: **OB-17: Previous C-section**
- In the preterm SGA/FGR fetus, middle cerebral artery (MCA) Doppler has limited accuracy to predict acidemia and adverse outcome; it should not be used to time delivery. Most studies investigating MCA Doppler as a predictor of adverse outcome in preterm SGA/FGR fetuses have reported low predictive value, especially when umbilical artery Doppler is abnormal. In the largest study of predictors of neonatal outcome in SGA/FGR neonates of less than 33 weeks gestational age (n = 604), it was not a statistically significant predictor of outcome on logistic regression, although MCA PI < -2 SDs was associated with neonatal death (LR 1.12, 95% CI 1.04–1.21) and major morbidity (LR 1.12, 95% CI 1.1–1.33).
- In addition, it has been found that umbilical artery Doppler studies are less reliable after 34 weeks as IUGR at 34 weeks or greater is typically characterized by milder placental dysfunction
- In the near-term SGA/FGR fetus with normal umbilical artery Doppler, an abnormal middle cerebral artery Doppler (PI <5th centile) has moderate predictive value for acidosis at birth and should be used to time delivery. MCA Doppler may be a more useful test in SGA/FGR fetuses detected after 34 weeks of gestation when umbilical artery Doppler is normal. Based on this evidence it is reasonable to use MCA Doppler to time delivery in the near term-term (34 weeks gestation or greater) SGA/FGR fetus with normal umbilical artery Doppler.

References

1. Reddy UM, Filly RA, and Copel JA. Prenatal Imaging: Ultrasonography and Magnetic Resonance Imaging. *Obstetrics and Gynecology*. 2008;112:145-157. Accessed November 14, 2017. <http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2008&issue=07000&article=00024&type=abstract>.
2. Sciscione AC, Hayes EJ. Uterine artery Doppler flow studies in obstetric practice. *American J of Obstet and Gynecol*. 2009;201(2):121-126. Accessed November 15, 2017. [http://www.ajog.org/article/S0002-9378\(09\)00283-X/fulltext](http://www.ajog.org/article/S0002-9378(09)00283-X/fulltext).
3. Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55 974 women. *Ultrasound in Obstetrics & Gynecology*. 2014;43(5):500-507. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.13275/epdf>.
4. Oros D, Figueras F, Cruz-Martinez R, et al. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. *Ultrasound Obstet Gynecol*. 2011;37:191-5. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7738/pdf>.
5. Practice Bulletin No. 145: Antepartum Fetal Surveillance. *Obstetrics & Gynecology*. 2014, reaffirmed 2016. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Citation/2014/07000/Practice_Bulletin_No_145_Antepartum_Fetal.35.aspx.
6. Practice Bulletin No. 175: Summary: Ultrasound in pregnancy. *Obstetrics & Gynecology*. 2016;128(6):1459-1460. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.
7. Practice Bulletin No. 134: Fetal Growth Restriction. *Obstetrics & Gynecology*. 2013; 121(5):1122-1133. Accessed November 15, 2017. http://journals.lww.com/greenjournal/Abstract/2013/05000/Practice_Bulletin_No_134_Fetal_Growth.45.aspx.
8. Galan HL. Timing Delivery of the Growth-Restricted Fetus. *Seminars in Perinatology*. 2011;35(5):262-269. doi:10.1053/j.semperi.2011.05.009

OB-24.10: Duplex Scan (Uterine Artery)

- Uterine artery Duplex (Doppler) scan (CPT® 93976), evaluation has been shown to predict adverse outcomes when utilized in the first and second trimester, prior to 16 weeks. The clinical utility, however, is limited to the first trimester when low dose Aspirin therapy can be instituted to decrease the risk of adverse outcomes (chronic hypertension, preeclampsia, and possibly FGR). Provider certification, study technique, and abnormal test thresholds have been established by the Fetal Medicine Foundation (similar to the certification process for Nuchal Translucency screening). The Society of Maternal Fetal Medicine (SMFM) has recommended the use of CPT® 93976 only.
- Prophylaxis is now possible if started prior to 16 weeks gestation. Therefore, the use of Uterine Artery Doppler evaluation is now justified when utilized before 16 weeks gestation for patients with chronic hypertension or who are at risk for preeclampsia.
- The CPT® code recommended by SMFM is CPT® 93976 only. Send to Medical Director review if beyond 16 weeks gestation. One time only study.

CPT® Code Guidance
CPT® 93975 describes a complete duplex scan and should be reported if an organ is evaluated in its entirety. A complete study involves the evaluation of the inflow and outflow vessels of one or more organs. This code is NOT used for obstetric imaging.
CPT® 93976 describes a limited duplex scan and should be reported when a complete study is not documented, for example, in the case of a follow-up study or a study of only the arterial flow.
CPT® 93976 is used to report a fetal umbilical-placental flow study .

References

1. Vergani P, Roncaglia N, Ghidini A, et al. Can adverse neonatal outcome be predicted in late preterm or term fetal growth restriction? *Ultrasound Obstet Gynecol.* 2010;36(2):166–70. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7583/abstract>.
2. Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. *Obstet Gynecol.* 2007;109:253–61. Accessed November 16, 2017. <http://journals.lww.com/greenjournal/Pages/articleviewer.aspx?year=2007&issue=02000&article=00004&type=Fulltext>.
3. Oros D, Figueras F, Cruz–Martinez R, et al. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. *Ultrasound Obstet Gynecol.* 2011;37:191–5. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.7738/pdf>.
4. Hershkovitz R, Kingdom JC, Geary M, et al. Fetal cerebral blood flow redistribution in late gestation: identification of compromise in small fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol.* 2000;15(3):209–12. Accessed November 15, 2017. <http://onlinelibrary.wiley.com/doi/10.1046/j.1469-0705.2000.00079.x/epdf>.
5. Severi FM, Bocchi C, Visentin A, et al. Uterine and fetal cerebral Doppler predict the outcome of third-trimester small-for-gestational age fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol.* 2002;19:225–8. Accessed November 15, 2017. https://www.researchgate.net/publication/11466710_Uterine_and_fetal_cerebral_Doppler_predict_the_outcome_of_third-trimester_small-for-gestational_age_fetuses_with_normal_umbilical_artery_Doppler.

6. Reddy UM, Filly RA, and Copel JA. Prenatal Imaging: Ultrasonography and Magnetic Resonance Imaging. *Obstetrics and Gynecology*. 2008;112(1):145-157. Accessed November 14, 2017.
<http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2008&issue=07000&article=00024&type=abstract>.
7. Sciscione AC, and Hayes EJ. Uterine artery Doppler flow studies in obstetric practice. *American J Obstet Gynecol*. 2009;201(2):121-126. Accessed November 15, 2017.
[http://www.ajog.org/article/S0002-9378\(09\)00283-X/fulltext](http://www.ajog.org/article/S0002-9378(09)00283-X/fulltext).
8. Stampalija T, Alfrevic Z, and Gyte G. Cochrane Reviews' summaries and their relevance for imaging. *Ultrasound Obstet Gynecol*. 2010;36(6):779-80. Accessed November 15, 2017.
<http://onlinelibrary.wiley.com/doi/10.1002/uog.8863/epdf>.
9. Practice Bulletin No. 134: Fetal Growth Restriction. *Obstetrics & Gynecology*. 2013; 121(5):1122-1133. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Abstract/2013/05000/Practice_Bulletin_No_134_Fetal_Growth_Restriction.45.aspx.
10. Practice Bulletin No. 145: Antepartum Fetal Surveillance. *Obstetrics & Gynecology*. 2014, reaffirmed 2016;124(1):182-192, reaffirmed in 2016. Accessed November 15, 2017.
http://journals.lww.com/greenjournal/Citation/2014/07000/Practice_Bulletin_No_145_Antepartum_Fetal_Surveillance.35.aspx.
11. Copel JA, and Bahtiyar MO. A practical approach to fetal growth restriction. *Obstetrics & Gynecology*. 2014;123(5):1057-1069. Accessed November 16, 2017.
http://journals.lww.com/greenjournal/Abstract/2014/05000/A_Practical_Approach_to_Fetal_Growth_Restriction.22.aspx.
12. Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55 974 women. *Ultrasound in Obstetrics & Gynecology*. 2014; 43(5):500-507. Accessed November 16, 2017.
<http://onlinelibrary.wiley.com/doi/10.1002/uog.13275/epdf>.

OB-24.11: Fetal Echocardiography

CPT® Code Guidance	
➤	It is inappropriate to report codes CPT® 76825 – CPT® 76828 for the routine monitoring of fetal heart tones using a hand-held or any Doppler device that does not create a hard-copy output. Such fetal heart tone monitoring is considered part of the physical examination and is not separately billable
➤	CPT® 76825 describes fetal echocardiography, real time with image documentation (2D), with or without M-mode recording
➤	CPT® 76826: ◆ is a follow-up or repeat fetal echocardiogram ◆ should never be billed with CPT® 76825 ◆ should never be billed more than once on any date of service
➤	CPT® 76827 describes a complete Doppler echocardiography, fetal, pulsed wave and/or continuous wave with spectral display
➤	CPT® 76828: is a follow-up or repeat Doppler fetal echocardiogram
➤	CPT® 93325 is used to report color mapping in conjunction with fetal echocardiography procedures CPT® 76825 – CPT® 76828.

Practice Notes

Doppler of the ductus venosus, Doppler of the ductus arteriosus, and PR Interval measurement.

- **Ductus venosus Doppler:** This is billable when sampled as part of a fetal echocardiogram study. Initial evaluation is reported as 76827; follow-up as 76828. Ductus Venosus Doppler is not billed when it is the sole assessment performed.
- **Ductus arteriosus Doppler:** This is often performed after another ultrasound study, so it is billed as 76828. If performed as part of an initial fetal echocardiogram evaluation, it is billed as 76827 then, and 76828 on subsequent studies.
- **PR interval measurement:** This is often performed after another ultrasound study, so it is billed as 76828. If performed as part of an initial fetal echocardiogram evaluation, it is billed as 76827 then, and 76828 on subsequent studies.

Reference

1. SMFM Coding Committee July 2017 Coding Tip #1: When and how are Ductus Venosus, Ductus Arteriosus and PR Intervals reported.

OB-24.12: 3D and 4D Rendering

- There is currently insufficient data to generate appropriateness criteria for the use of 3D and 4D rendering in conjunction with ultrasound.
- Current guidelines on ultrasonography in pregnancy from ACOG state: "The technical advantages of 3-dimensional ultrasonography include its ability to acquire and manipulate an infinite number of planes and to display ultrasound planes traditionally inaccessible by 2-dimensional ultrasonography. Despite these technical advantages, proof of a clinical advantage of 3-dimensional ultrasonography in prenatal diagnosis, in general, is still lacking. Potential areas of promise include fetal facial anomalies, neural tube defects, and skeletal malformations where 3-dimensional ultrasonography may be helpful in diagnosis as an adjunct to, but not a replacement for, 2-dimensional ultrasonography."
- Yagel et al described the state of the science of 3D/4D ultrasound (3D/4D US) applications in fetal medicine. They noted that 3D/4D US applications are many and varied. Their use in fetal medicine varies with the nature of the tissue to be imaged and the challenges each organ system presents, versus the advantages of each ultrasound application. The investigators stated that 3D/4D US has been extensively applied to the study of the fetus. Fetal applications include all types of anatomical assessment, morphometry, and volumetry, as well as functional assessment. The authors concluded that 3D/4D US provides many advantages in fetal imaging; however, its contribution to improving the accuracy of fetal scanning over rates achieved with 2D US, remains to be established.
- Clinical use of 3D ultrasound should be on an individual basis. There can be specific reasons that require 3D ultrasound when 2D cannot be utilized. Such as determination of fetal growth when there is absence of lower limbs / femurs. Since the femur length is vital in determination of fetal weight and growth. Fractional limb volume measurement of the humerus is required to evaluate for FGR.
- A second clinical scenario is seen with gastroschisis. Since the fetal abdomen is small due to the defect present, there is artificially high rate of FGR. The cause of this is the use of the fetal abdominal circumference to determine growth. 3D Fractional limb volume measurement eliminates this issue and decreases false positives.

References

1. Lee W, Deter R, Sangi-Haghpeykar H, et al. Prospective validation of fetal weight estimation using fractional limb volume. *Ultrasound Obstet Gynecol.* 2013;41(2):198-203. Accessed November 16, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/uog.11185/epdf>.
2. Reddy UM, Filly RA, and Copel JA. Prenatal Imaging. *Ultrasonography and Magnetic Resonance Imaging. Obstetrics & Gynecology.* 2008;112(1):145-157. Accessed November 14, 2017. <http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2008&issue=07000&article=00024&type=abstract>.
3. Practice Bulletin No. 175 Summary: Ultrasound in pregnancy. *Obstet & Gynecol.* 2016;128(6):1459-1460. Accessed November 3, 2017. http://journals.lww.com/greenjournal/Abstract/2016/12000/Practice_Bulletin_No_175_Summary_Ultrasound_in.50.aspx.
4. Merz E, Abramowicz JS. 3D/4D ultrasound in prenatal diagnosis: is it time for routine use? *Clin Obstet Gynecol.* Mar 2012;55(1):336-51. Accessed November 16, 2017. <https://www.medscape.com/medline/abstract/22343249>.

OB-24.13: Fetal MRI

CPT® Code Guidance	
➤	Fetal MRI (CPT® 74712) ; for each additional gestation (CPT® 74713)
➤	Do not report CPT® 74712 and CPT® 74713 in conjunction with CPT® 72195, CPT® 72196, CPT® 72197
➤	If only placenta or maternal pelvis is imaged without fetal imaging, use MRI pelvis (CPT® 72195)

Indications for fetal MRI

- Fetal MRI may be considered for surgical planning (re: fetal anomalies), and/or if an ultrasound is equivocal **and** additional information is needed for counseling purposes, for indications including the following:
 - ◆ Brain
 - Congenital anomalies
 - ventriculomegaly
 - corpus callosal dysgenesis
 - holoprosencephaly
 - posterior fossa anomalies
 - malformations of cerebral cortical development
 - Screening fetuses with a family risk for brain anomalies
 - tuberous sclerosis
 - corpus callosal dysgenesis
 - malformations of cerebral cortical development
 - Vascular abnormalities
 - vascular malformations
 - hydranencephaly
 - infarctions
 - monochorionic twin pregnancy complications
 - ◆ Spine
 - Congenital anomalies
 - neural tube defects
 - sacrococcygeal teratomas
 - caudal regression/sacral agenesis
 - sirenomelia
 - vertebral anomalies
 - ◆ Skull, face, and neck
 - Masses of the face and neck
 - venolymphatic malformations
 - hemangiomas
 - goiter
 - teratomas
 - facial clefts
 - Airway obstruction
 - conditions that may impact parental counseling, prenatal management, delivery planning, and postnatal therapy

- ◆ Thorax
 - Masses
 - congenital pulmonary airway malformations (congenital cystic adenomatoid malformation; sequestration, and congenital lobar emphysema);
 - congenital diaphragmatic hernia
 - effusion
 - Volumetric assessment of lung
 - cases at risk for pulmonary hypoplasia secondary to oligohydramnios, chest mass, or skeletal dysplasias
- ◆ Abdomen, retroperitoneal and pelvis
 - Mass
 - abdominal–pelvic cyst
 - tumors (e.g. hemangiomas, neuroblastomas, sacrococcygeal teratomas, and suprarenal or renal masses)
 - complex genitourinary anomalies (e.g. cloaca)
 - renal anomalies in cases of severe oligohydramnios
 - bowel anomalies such as megacystis microcolon
- ◆ Complications of monochorionic twins
 - delineation of vascular anatomy prior to laser treatment of twins
 - assessment of morbidity after death of a monochorionic co-twin
 - improved delineation of anatomy in conjoined twins
- ◆ Fetal surgery assessment
 - meningocele
 - sacrococcygeal teratomas
 - processes obstructing the airway (e.g. neck mass or congenital high airway obstruction)
 - complications of monochorionic twins needing surgery
 - chest masses

References

1. Saleem SN. Fetal MRI: An approach to practice: A review. Journal of Advanced Research. 2014; 5(5):507-523. ~American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR-SPR practice guideline for the safe and optimal performance of fetal magnetic resonance imaging (MRI). American College of Radiology (ACR); 2010:10. <http://www.guidelines.gov/content.aspx?id=32509>.
2. Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ et al. MRI of placenta Accreta, Placenta Increta and Placenta Percreta: Pearls and Pitfalls. American Journal of Roentgenology. 2017; 208(1):214-221. Accessed November 16, 2017. <http://www.ajronline.org/doi/pdf/10.2214/AJR.16.16281>
3. Uma M. Reddy, MD, MPH, Alfred Z. Abuhamad, MD, Deborah Levine, MD, and George R. Saade, MD, for the Fetal Imaging Workshop Invited Participants* Fetal Imaging Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop Obstet Gynecol 2014;123:1070–82)
4. American College of Radiology. ACR–SPR practice guideline for the safe and optimal performance of fetal magnetic resonance imaging (MRI). Revised 2010 (Resolution 13).
5. Belfort MA. Placenta accreta. American Journal of Obstetrics and Gynecology. 2010;203(5):430-439. doi:10.1016/j.ajog.2010.09.013

OB-25: High Risk Medications and Substances

- Specific drugs that qualify as risk factors in High Risk Pregnancy and qualify as medical indications for Specialized Fetal Anatomic Scan (CPT® 76811): If another high risk indication see appropriate guideline for any further imaging

Practice note

This list is by no means all inclusive

High Risk Medications/Substances
Alcohol
Aminoglycosides (amikacin, gentamycin, kanamycin, tobramycin, and other mycins)
Amphetamines
Angiotensin II antagonists or blockers
Anti-neoplastics (cancer drugs)
Accutane/isoretinoin/retinoic acid
Aspirin – only if exposed less than 10 weeks gestation
Atenolol
ACE inhibitors (benzapril, captopril, enalapril, fosinopril, lisinipril, etc)
Anticonvulsants (phenytoin, carbamazepine, valproate, primidone, phenobarbital, Dilantin)
Azathioprine
Benzodiazepines (Diazepam (valium), etc)
Carbon monoxide
Chlordiazepoxide
Cocaine
Codeine
Cortisone
Coumadin/ warfarin
Cyclophosphamide
Cytarabine
Daunorubicin
Dextroamphetamine
Ergotamine
Fluconazole (and other anti-fungals)
Heparin
Lithium
Methimazole
Methotrexate
Methyl mercury
Misoprostol
Oral contraceptives
Paramethadione
Paroxetine/SSRI
Penicillamine
Primidone
Progesterones (exposure less than 12 weeks) and anti-progesterone drug RU486
Pregabalin/Lyrica
Quinine

Retinoic acid/retinoid medications
Selective serotonin reuptake inhibitors (SSRI)
Substance abuse (heroin, methadone, subutex, cocaine)
Tetracyclines
Thalidomide
Trifluoperazine
Trimethadione
Valproic acid

References

1. Practice Bulletin No. 92: Use of Psychiatric Medications During Pregnancy and Lactation. 2008; 111(4):1001-1020, Reaffirmed 2016. Accessed November 16, 2017. <http://journals.lww.com/greenjournal/pages/collectiondetails.aspx?TopicalCollectionID=37>.
2. Drugs in Pregnancy and Lactation: Improved Benefit-Risk information. FDA/CDER SBIA Chronicles, January 22. 2015. Accessed November 16, 2017. <https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf>
3. Burkey, B, and Holmes, A. Evaluating Medication Use in Pregnancy and Lactation: What Every Pharmacist Should Know. J Pediatr Pharmacol Ther. 2013;18(3): 247-258. Accessed November 16, 2017. <http://www.jppt.org/doi/abs/10.5863/1551-6776-18.3.247?code=ppag-site>
4. Mascola MA, Borders AE, Terplan M. Committee Opinion No. 711 Summary. Obstetrics & Gynecology. 2017;130(2):488-489. <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-in-Pregnancy>. Accessed August 10, 2018.

OB-26: Imaging for Planned Pregnancy Termination

- For a planned pregnancy termination, ultrasound can be performed to determine intrauterine pregnancy and gestational age.
 - ◆ One complete ultrasound (CPT® 76801) and/or one transvaginal ultrasound (CPT® 76817), if less than 14 weeks
 - ◆ If ≥ 14 weeks, send to MD review. Imaging may be indicated to confirm EGA, placenta location, and/or fetal anomalies

References

1. Practice Bulletin No. 143. Obstetrics & Gynecology. 2014;123(3):676-692. doi:10.1097/01.aog.0000444454.67279.7d Reaffirmed 2016.
2. Practice Bulletin No. 135. Obstetrics & Gynecology. 2013;121(6):1394-1406. doi:10.1097/01.aog.0000431056.79334.cc. Reaffirmed 2017.